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ABSTRACT 
Background: Limited research has been done to monitor the progression of health 
outcomes in individuals with Parkinson's disease (PD) and acquired brain injury 
(ABI).  
Objective/Hypothesis: The purpose of this longitudinal study was to assess the 
natural progression of the disease process and its effects on nutritional status, 
cognition, and cardiometabolic risk over a two year time period in those living with 
PD and ABI >12 months post-diagnosis. 
Methods: Thirteen community-dwelling adults (9 with PD and 4 with ABI) were 
evaluated for nutritional status using the dietary screening tool (DST), cognition using 
the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 
and cardiometabolic risk factors using anthropometric, biochemical, and clinical 
assessments. Three evaluations separated by 6-12 month increments for each 
participant took place. Changes in nutritional status, cognition, and cardiometabolic 
risk were assessed using RMANCOVA (p<0.05).  
Results: Of the 9 participants with PD, 6 (66.7%) did not change nutritional risk 
categories over time; 2 worsened and 1 improved. Of the 4 participants with ABI, 2 
(50%) did not change nutritional risk categories over time; 1 improved and 1 
worsened. Time appeared to have a negative effect on cognition for participants with 
PD and a positive effect on cognition for participants with ABI. Six PD and 2 ABI 
participants had no change or fewer cardiometabolic risk factors over time, while 1 PD 
and 1 ABI had more cardiometabolic risk factors over time. Findings however were 
not statistically significant. 
  
 
Conclusion: Our data reinforces the notion of outcome heterogeneity in individuals 
with PD and ABI. Since nutritional status, cognition, and cardiometabolic risk factors 
are unique to each patient, it is of clinical importance to provide evaluation and 
treatment on an individual basis. More consistent, long-term evaluations are needed to 
detect disease progression trends and determine what risk factors occur when to guide 
intervention development. 
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PREFACE 
This thesis was written to comply with the University of Rhode Island graduate 
school Manuscript Thesis Format. This thesis contains one manuscript: Nutritional 
Status, Cognition, and Cardiometabolic Risk in Individuals with Neurological 
Disorders. This manuscript has been written in a form suitable for publication in 
Disability and Health Journal. 
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ABSTRACT 
 
Background: Limited research has been done to monitor the progression of health 
outcomes in individuals with Parkinson's disease (PD) and acquired brain injury 
(ABI).  
Objective/Hypothesis: The purpose of this longitudinal study was to assess the 
natural progression of the disease process and its effects on nutritional status, 
cognition, and cardiometabolic risk over a two year time period in those living with 
PD and ABI >12 months post-diagnosis. 
Methods: Thirteen community-dwelling adults (9 with PD and 4 with ABI) were 
evaluated for nutritional status using the dietary screening tool (DST), cognition using 
the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 
and cardiometabolic risk factors using anthropometric, biochemical, and clinical 
assessments. Three evaluations separated by 6-12 month increments for each 
participant took place. Changes in nutritional status, cognition, and cardiometabolic 
risk were assessed using RMANCOVA (p<0.05).  
Results: Of the 9 participants with PD, 6 (66.7%) did not change nutritional risk 
categories over time; 2 worsened and 1 improved. Of the 4 participants with ABI, 2 
(50%) did not change nutritional risk categories over time; 1 improved and 1 
worsened. Time appeared to have a negative effect on cognition for participants with 
PD and a positive effect on cognition for participants with ABI. Six PD and 2 ABI 
participants had no change or fewer cardiometabolic risk factors over time, while 1 PD 
and 1 ABI had more cardiometabolic risk factors over time. Findings however were 
not statistically significant. 
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Conclusion: Our data reinforces the notion of outcome heterogeneity in individuals 
with PD and ABI. Since nutritional status, cognition, and cardiometabolic risk factors 
are unique to each patient, it is of clinical importance to provide evaluation and 
treatment on an individual basis. More consistent, long-term evaluations are needed to 
detect disease progression trends and determine what risk factors occur when to guide 
intervention development. 
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INTRODUCTION 
Parkinson's disease (PD), traumatic brain injury (TBI), and stroke are unique 
neurological diagnoses that share common symptoms and risk factors for decline in 
the areas of nutritional status, cognitive function, and cardiometabolic risk.1-5 
Parkinson’s disease is a neurodegenerative movement disorder that worsens over 
time.6 Traumatic brain injury (TBI) and stroke are two types of acquired brain injury 
(ABI) that cause damage to the brain.7 These conditions may decrease life expectancy 
by as much as 33 years compared to healthy populations, 8-10 and individuals with 
these diagnoses experience declines that can negatively impact nutritional status, 
cognitive function, and cardiometabolic risk earlier in life. 2, 7, 9-14 
While health status at the time of diagnosis or immediately after diagnosis has 
been studied, limited research has been done to monitor the progression of nutritional 
status, cognition, and cardiometabolic risk factors in individuals living with PD or 
ABI.1-3 Earlier and faster deteriorations in these health outcomes can lead to chronic 
diseases such as cardiovascular disease (CVD) and can negatively influence quality of 
life sooner.15 Consistent, regular monitoring of these outcomes in those with PD and 
ABI is critical to determine how these populations differ from the general population. 
Furthermore, knowledge of how and when these specific neurological disorders 
impact these outcomes will allow for earlier and more targeted interventions to 
attenuate disease evolution. The purpose of this longitudinal study is to assess the 
natural evolution of the disease process on nutritional status, cognition, and 
cardiometabolic risk factors over a time frame of 12-18 months in those living with 
PD and ABI >12 months post-diagnosis.  
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MATERIALS AND METHODS 
Design 
This study assessing nutritional status, cognitive function, and cardiometabolic 
risk factors in those with PD or ABI is an ancillary portion of a five-year longitudinal, 
observational study. Evaluations are administered every six months and use a variety 
of metrics to assess participants’ characteristics. Study approval was obtained from the 
University of Rhode Island’s Institutional Review Board (IRB HU#1314-006). This 
ancillary study will expand upon the previous cross-sectional assessment performed in 
this population by LoBuono et al.11 
Participants, setting, and recruitment 
Participants (18-85 years of age) diagnosed with PD or ABI for at least 12 
months and determined to be medically stable by a neurologist were recruited on a 
rolling basis via brochures and word-of-mouth. Before entering into the study, all 
participants completed the informed consent process. Participant evaluations occurred 
once every six months. Specifically, this report will focus on participants who have 
completed their first time point (T1) and two additional follow-up visits (T2 and T3) 
in 12-18 months following T1. 
Assessment visit and data collection 
At each assessment, participants completed a medical history questionnaire 
and a multidisciplinary assessment in the areas of nutrition, cognition, and 
cardiometabolic risk factors. 
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Procedures/Measures 
Nutritional Status- Nutritional status was assessed using the Dietary Screening 
Tool (DST).16, 17 The DST identifies dietary patterns and characterizes three levels of 
nutrition risk based on dietary quality using a 25-item questionnaire. A total of 100 
points can be achieved with cutoff scores for nutrition risk as follows: at risk (<60), 
possible risk (60-75), and not at risk (>75).16, 17   
Cognition- Cognition was assessed using the Repeatable Battery for the 
Assessment of Neuropsychological Status (RBANS).18 The RBANS is a measurement 
of neuropsychological status comprised of 12 subtests that measure 5 cognitive 
domains: 1. immediate memory, 2. visuospatial/constructional, 3. language, 4. 
attention, and 5. delayed memory. Each of the five index scores are added together for 
a total score. Scores are scale-corrected based on normative information by age and 
education level and have a mean of 100±15, with lower scores indicative of greater 
cognitive impairment.19  
Cardiometabolic Risk- Cardiometabolic risk factors assessed in this study 
were the anthropometric, biochemical, and clinical modifiable risk factors identified 
by the American Diabetes Association and the American College of Cardiology 
Foundation in the concept of global cardiometabolic risk.20-23 These factors are: 1. 
overweight or obesity, 2. hypertension, 3. dyslipidemia, and 4. hyperglycemia. Height 
(cm), measured using a stadiometer (Deteco, Webb City Missouri), and weight (kg), 
measured using a scale (Tanita BF-556, Arlington Heights, Illinois), were used to 
calculate body mass index (BMI) (kg/height in meters2) and determine weight status. 
Blood pressure was measured using an automatic blood pressure machine (Omron 
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Healthcare Inc., Bannockburin Illinois). Following a 12-hour fast, plasma total 
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TAG), 
and glucose were analyzed using the portable Cholestech® machine (Cholestech® 
LDX system, Hayward California), while LDL-C was calculated using the Friedewald 
formula.24-26 Participants were considered overweight if BMI >25kg/m2 and obese if 
BMI >30kg/m2. A systolic blood pressure (SBP) >140mm Hg and diastolic blood 
pressure (DBP) >90mm Hg was considered hypertensive. Abnormal biochemical lab 
values were as follows: TC >200mg/dL, HDL-C <40mg/dL, LDL-C >100mg/dL, 
TAG >150mg/dL, and glucose >100mg/dL. 
Statistical Analysis 
Data were analyzed using SPSS, version 23.0 (IBM Corp. Somers, NY). 
Descriptive statistics were performed and normality assessed using the Shapiro-Wilk 
test. A log-transformation of HDL-C was used to analyze the data. Age was not 
transformed and thus non-parametric tests were used. Between group differences at T1 
were determined via independent sample t-tests, Mann-Whitney U tests, and Fisher’s 
exact test. The primary aim of assessing nutritional status over time was tested using a 
repeated measures analysis of covariance (RMANCOVA) looking at the dependent 
variable of nutritional status as measured by DST score. Analysis of covariance 
(ANCOVA) was used to assess the relationship at T1 of nutritional status on 
cardiometabolic risk factors and cognitive function over time using with DST risk 
category as the independent variable. Cognitive function as RBANS score and the 
number of cardiometabolic risk factors served as the dependent variables. Covariates 
included were length of time since diagnosis and age, except for RBANS scores which 
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are already age adjusted. Neither time since diagnosis nor age were found to be 
significant covariates in explaining any of the key dependent measures and thus were 
not used for analysis in results presented here. For analyses in violation of Mauchly's 
test of sphericity, results were interpreted using the Greenhouse-Geisser correction. 
Analyses were considered significant when p < 0.05. 
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RESULTS 
A total of 16 participants consented to participate in the study. Two passed 
away after their first assessments and one was unable to attend a third assessment for 
personal reasons. Thus, 13 participants who completed three assessments separated by 
12-18 months were included in data analyses. Participant characteristics are in Tables 
1 and 2. Most were male (n=10, 76.9%) and were diagnosed with PD (n=9, 69.2%). 
Eight participants were taking medication to manage blood pressure and/or lipids, 
including one participant taking diabetes medication. 
 Participants with PD were significantly older than participants with ABI 
(67.7±3.9 vs. 49.0±16.2, p=0.02). Participants with PD scored significantly higher 
scores on the RBANS indexes of language (97.2±8.5 vs. 80.0±2.3, p=0.002) and 
attention (93.6±10.7 vs. 56.0±15.9, p=0.001) as well as total RBANS score (85.6±13.7 
vs. 66.5±13.2, p=0.04) at T1 than participants with ABI. 
Nutritional Status 
There were no significant differences in nutritional risk within or between 
groups over time as measured by the DST (Figure 1).  Furthermore, no significant 
relationship was found between nutritional status and any of the cardiometabolic risk 
factors or RBANS indexes over time. At T1, 11 (84.6%) participants were “at 
nutrition risk” or “at possible nutritional risk” (8 PD and 3 ABI).   
Eight participants did not change nutritional risk categories over time. Six of 
the 8 were participants with PD; 2 stayed “at nutritional risk,” 3 stayed “at possible 
nutritional risk,” and 1 stayed “not at nutritional risk.” The remaining 2 of the 8 were 
participants with ABI; both stayed “at possible nutritional risk.”  
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Five participants changed nutritional risk categories over time. Three of the 8 
were participants with PD; 2 worsened from “at possible nutritional risk” to “at 
nutritional risk”, while 1 improved from “at nutritional risk” to “at possible nutritional 
risk.” One participant with ABI worsened from “not at nutritional risk” to “at possible 
nutritional risk” and 1 participant with ABI improved from “at possible nutritional 
risk” to “not at nutritional risk”. 
Cognition 
There were no significant differences within or between groups over time in 
any index score or total RBANS score over time.  
Although not significant, time appeared to effect measures of cognition for all 
participants. There was a different trajectory between groups, with a decrease in all 
RBANS scores for participants with PD and an increase in all RBANS scores for 
participants with ABI except in the index of attention (Tables 1 and 2).  
Cardiometabolic Risk Factors 
Total cholesterol, HDL-C, LDL-C, TAG, DBP and glucose concentrations did 
not significantly differ between or within groups over time. However, there was a 
significant effect for time on SBP in ABI participants (p=0.01) (Table 2). Weight 
significantly decreased over time in participants with PD (p=0.001) and BMI trended 
toward significance (p=0.06).  
All participants had at least one cardiometabolic risk factor at T1 and T2 
(Table 3). The most prevalent risk factor at T1 was BMI >25 kg/m2 (7 PD and 2 ABI). 
Seven (53.8%) participants remained overweight or obese at all time points (5 PD and 
2 ABI). Six PD participants had no change or fewer risk factors over time, while 1 
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increased over time. Two PD participants had elevated LDL-C at all time points; 2 
remained with elevated SBP, 2 maintained elevated glucose, and 3 maintained low 
HDL-C. Two ABI participants had no change or fewer risk factors over time, while 1 
increased over time. One ABI participant had elevated LDL-C at all time points. Two 
ABI participants maintained elevated TC, and 2 maintained elevated BMI over all 
time points. 
 
 12 
 
DISCUSSION 
To our knowledge, this study is the first to explore the evolution of nutritional 
status, cognition, and cardiometabolic risk over time in individuals with PD and ABI. 
This study showed that there is significant variability within groups of the same 
disease state and demonstrates the clinical importance of considering patients on an 
individual basis. 
 Routine assessments for individuals with PD and ABI remains imperative. 
Our results showed that a majority of participants remained at poor nutritional status 
or declined over time. Individuals may be at nutritional risk due to similar deleterious 
sequelae that can occur across all three disease states including problems with 
chewing, swallowing, and motor skills.27-29 While those with PD may be at increased 
nutritional risk due to a tendency to crave sweet foods or carbohydrates,30 research on 
dietary habits of individuals post TBI and stroke are lacking. Current findings 
establish the importance of using a dietary screening tool such as the DST in these 
populations. Dietary screening can be an effective strategy for early detection of those 
with compromised dietary intake to reduce nutritional risk and the burden of 
neurological disorders.16 However, validation of the DST is needed in these 
populations. Consistent with previous literature demonstrating PD patients 
continuously lose weight despite consuming a diet higher in energy content and lower 
in diet quality,31 our results showed that individuals with PD experienced weight loss 
while remaining “at” or “possibly at” nutrition risk. This weight loss exemplifies one 
of the many unexplained burdens of chronic neurological disorders, and may be 
attributed to the progressive nature of the disease. Additional research is warranted to 
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determine whether nutrition education can prevent weight loss to maintain or improve 
quality of life. While previous research on individuals post ABI have shown weight 
loss and poor nutritional status after the initial injury, data on long term weight and 
nutritional status has been limited.27, 32 The preliminary results of our longitudinal 
assessments with a small sample size indicate that individuals with ABI appear to 
maintain weight and nutritional status. The small sample of participants with TBI and 
stroke in the current study prevented a comparison between types of ABI. 
Participants with ABI consistently scored the lowest on the attention index of 
the RBANS; a deficit consistent with previous research findings.33, 34 These deficits 
result in an inability to focus and self-regulate, which may negatively impact 
nutritional status by hindering meal planning, food shopping, and meal completion. 
While participants with PD in this study did better than those with ABI in all of the 
RBANS indexes, deficits were most prominent in the area of immediate memory. It 
appears that this area of cognition might be more vulnerable in the PD population.35 
Deficits in immediate memory may negatively impact nutritional status by interfering 
with meal preparation, as well as shopping and eating.36 The non-significant trajectory 
shown in this study of cognitive decline in PD is consistent with previous literature 
associating declines with the duration of the disease.2 Results showing a non-
significant trajectory toward an increase in cognitive status in ABI are novel, but may 
be related to the average time since diagnosis of over 17 years. It is possible that 
individuals with ABI may be more likely to seek activities to improve cognitive 
decline than individuals with PD whose cognitive decline occurs gradually. 
Continuous evaluation of this trend will occur during the remainder of this five-year 
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study. Previous research in individuals post stroke found stable cognition two years 
post injury3 while significant variability in outcomes has been seen up to 5 years post 
TBI.33 Large effect sizes suggest that future studies with greater power may find 
clinically significant improvements over time in cognition in individuals with ABI 
diagnosed >10 years prior.  
Previous research has shown hypertension to be one of the most frequent 
cardiometabolic risk factors in participants with PD.5 However, our most prominent 
cardiometabolic risk factor was elevated BMI. This may be due to the use of 
medications to manage blood pressure and lipids by a majority of participants 
(61.5%), Two participants with PD maintained impaired fasting glucose across all 
three time points, one with diagnosed diabetes. While diabetes has been associated 
with chronic neurodegeneration and it is hypothesized that chronic hyperglycemia 
may exacerbate the severity of the motor disability37, 38, evidence associating diabetes 
and PD is inconclusive. Our results lend support to recommendations for individuals 
with PD to receive routine glucose monitoring.35 Additionally, our results are in 
agreement with previous studies demonstrating that cardiometabolic risk factors are 
often suboptimally managed after TBI and stroke, as two of the participants with ABI 
maintained hypercholesterolemia over all three time points.39, 40 More consistent 
assessments and active involvement by a multidisciplinary team of medical personnel 
in the management of these modifiable risk factors is necessary to help mitigate 
disease progression and the risk of recurrent stroke.39, 40  
Although it appeared that there were differences over time in total cholesterol 
and between group differences in LDL-C, HDL-C and RBANS scores, our sample 
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size may have been too small to detect differences. Studies with larger samples may 
wish to explore these variables further. 
Study strengths and limitations 
This is the first study to report on multiple assessments of the effects of the 
evolution of the disease process in the areas of nutrition, cognition, and 
cardiometabolic risk factors in those living with PD or ABI. Despite the important 
results this study presents, several limitations must be taken into consideration. Due to 
our small sample size, generalizability to larger populations is limited. However, 
looking at data individually is of clinical importance; since nutritional status, 
cognition, and cardiometabolic risk factors are unique to each patient, it is necessary to 
provide evaluation and treatment on an individual basis. Furthermore, this longitudinal 
study was non-experimental and therefore causation of results cannot be determined. 
Nonetheless, our longitudinal design was consistent with the goals of this research to 
observe disease evolution and individualize goals of treatment in the respective 
populations. Individuals in this study were all community-dwelling, and not 
representative of the PD or ABI populations as a whole. Future studies should include 
a larger sample size for a deeper understanding of the relationship of the progression 
of the disease process and its relationship to nutrition, cognition, and cardiometabolic 
risk factors. Additional longitudinal assessments with a longer period of follow up are 
warranted for a deeper understanding of the changes that occur in the disease process 
over time. Comparing participants with PD or ABI to age-matched healthy controls in 
future studies would help to see how participants with neurological disorders differ 
than the general population. 
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CONCLUSION 
Our data reinforces the notion of outcome heterogeneity in individuals with PD 
and ABI. Nutritional status, cognition, and cardiometabolic risk may change over time 
in individuals with PD and ABI. Consistent assessments of these health outcomes 
should be conducted regularly to identify and/or prevent the development of later-
onset complications. Identification of which health outcomes are most prominent and 
who is at greatest risk is necessary to interrupt the disease process as early as possible 
after diagnosis.41 
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TABLES AND FIGURES 
Table 1. PD Participant Characteristics and Within Group Changes Over Time 
 PD  
(n=9) 
P-value Effect 
Size 
Time point 1 2 3   
Age (years) 67.7±3.9*     
Time since Diagnosis (years)  7.1±7.2     
Gender %(n) 
     Men 
     Women 
 
88.9(8) 
11.1(1) 
    
Height (cm) 170.7±6.0 169.7±6.6 169.9±6.6 0.27 0.150 
Weight (kg) 79.2±12.7a 77.9±12.6ab 75.7±13.7b 0.001 0.562 
BMI (kg/m2) 27.1±3.2 26.9±3.1 26.2±3.8 0.06 0.298 
BMI Categories %(n) 
     Normal 
     Overweight 
     Obese 
 
33.3(3) 
55.6(4) 
11.1(1) 
 
33.3(3) 
44.4(4) 
22.2(2) 
 
44.4(4) 
44.4(4) 
11.1(1) 
  
DST Total 61.2±12.8 65.6±11.3 58.8±14.1 0.07 0.287 
DST Categories %(n) 
     At Nutritional Risk 
     Possible Nutritional Risk 
     Not at Nutritional  Risk 
 
33.3(3) 
55.6(4) 
11.1(1) 
 
23.1(3) 
44.4(4) 
22.2(2) 
 
44.4(4) 
44.4(4) 
11.1(1) 
  
Total cholesterol (mmol/L) 9.1±1.9† 8.5±1.5 8.3±1.2 0.23 0.192 
HDL-C (mmol/L)# 2.2±0.7† 2.1±0.6 2.1±0.5 0.88 0.018 
LDL-C (mmol/L) 5.4±1.6† 5.2±1.3 4.8±1.5 0.31 0.155 
Triglycerides (mmol/L) 7.4±3.7† 5.6±1.7 6.9±2.5 0.28 0.165 
Glucose (mmol/L) 5.6±1.0‡ 5.2±0.9 5.5±1.0 0.24 0.218 
Systolic BP (mm Hg) 139.6±22.9 132.3±14.6 144.7±17.4 0.29 0.143 
Diastolic BP (mm Hg) 82.0±11.1 79.7±6.2 81.4±13.4 0.88 0.016 
RBANS Total 85.6±13.7* 82.8±16.3 80.0±15.1 0.16 0.208 
Immediate Memory 85.4±14.6 76.8±17.2 79.4±19.0 0.30 0.141 
Visuospatial/ 
Constructional 
86.8±15.1 84.4±24.3 79.6±17.9 0.42 0.102 
Language 97.2±8.5** 93.6±8.6 91.1±10.5 0.21 0.179 
Attention 93.6±10.7*** 88.1±19.6 88.7±15.1 0.33 0.128 
Delayed Memory 84.8±22.7 90.4±15.7 82.7±22.1 0.09 0.298 
Notes: values expressed as mean± standard deviation. Differences between groups for all normally distributed variables analyzed 
using independent t-tests.*Difference between PD vs. ABI  p < .05; **Difference between PD vs. ABI  p < .005; ***Difference 
between PD vs. ABI p < .0005; †n=8; ‡n=7; 
§n=3; #Log-transformed for analysis 
Abbreviations: BMI, body mass index; DST, dietary screening tool; HDL-C, high density lipoprotein cholesterol; LDL-C, low 
density lipoprotein cholesterol; BP, blood pressure; RBANS, Repeatable Battery for the Assessment of Neuropsychological 
Status.; BMI: Normal = 18.5-24.9 kg/m2, Overweight = 25.0-29.9 kg/m2, Obese = >30.0 kg/m2; DST: At Nutritional Risk = <60, 
Possible Nutritional Risk = 60-75, Not at Nutritional Risk = >75 
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Table 2. ABI Participant Characteristics and Within Group Changes Over Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: values expressed as mean± standard deviation. Differences between groups for all normally distributed variables analyzed 
using independent t-tests.*Difference between PD vs. ABI  p < .05; **Difference between PD vs. ABI  p < .005; ***Difference 
between PD vs. ABI p < .0005; †n=8; ‡n=7; 
§n=3; #Log-transformed for analysis 
Abbreviations: BMI, body mass index; DST, dietary screening tool; HDL-C, high density lipoprotein cholesterol; LDL-C, low 
density lipoprotein cholesterol; BP, blood pressure; RBANS, Repeatable Battery for the Assessment of Neuropsychological 
Status.; BMI: Normal = 18.5-24.9 kg/m2, Overweight = 25.0-29.9 kg/m2, Obese = >30.0 kg/m2; DST: At Nutritional Risk = <60, 
Possible Nutritional Risk = 60-75, Not at Nutritional Risk = >75 
 
 
 ABI  
(n=4) 
P-value Effect Size 
Time point 1 2 3   
Age (years) 49.0±16.1*     
Time since Diagnosis (years) 17.0±8.7     
Gender %(n) 
     Men 
     Women 
 
50.0(2) 
50.0(2) 
    
Height (cm) 169.4±14.1 169.0±14.5 169.4±14.7 0.73 0.101 
Weight (kg) 75.7±18.7 75.1±18.0 73.8±18.1 0.11 0.528 
BMI (kg/m2) 26.0±2.3 25.2±1.6 25.3±2.2 0.65 0.133 
BMI Categories %(n) 
     Normal 
     Overweight 
     Obese 
 
25.0(1) 
75.0(3) 
0.0(0) 
 
25.0(1) 
75.0(3) 
0.0(0) 
 
50.0(2) 
50.0(2) 
0.0(0) 
  
DST Total 70.8±7.0 66.8±7.9 70.3±6.0 0.40 0.640 
DST Categories %(n) 
     At Nutritional Risk 
     Possible Nutritional Risk 
     Not at Nutritional  Risk 
 
0.0(0) 
75.0(3) 
25.0(1) 
 
0.00(0) 
75.0(3) 
25.0(1) 
 
0.00(0) 
75.0(3) 
25.0(1) 
  
 
 
Total cholesterol (mmol/L) 11.5±2.3 10.6±1.9 10.8±2.0§ 0.33 0.420 
HDL-C (mmol/L)# 3.3±1.9 3.4±1.7 4.4±1.4§ 0.49 0.520 
LDL-C (mmol/L) 5.6±2.4 5.6±1.9 5.6±2.5§ 0.83 0.073 
Triglycerides (mmol/L) 7.1±4.1 7.7±3.9 6.7±4.6§ 0.09 0.700 
Glucose (mmol/L) 4.5±1.0 5.0±0.5 4.8±0.7§ 0.44 0.338 
Systolic BP (mm Hg) 124.0±8.8 115.1±4.3 122.8±8.3 0.01 0.757 
Diastolic BP (mm Hg) 76.5±7.2 73.6±7.3 73.3±6.3 0.11 0.526 
RBANS Total 66.5±13.2* 67.0±16.6 72.5±16.0 0.15 0.472 
Immediate Memory 68.8±22.6 66.3±18.2 74.5±24.2 0.33 0.307 
Visuospatial/ 
Constructional 
78.0±10.7 80.3±24.3 89.3±22.6 0.17 0.450 
Language 80.0±2.3** 70.5±13.8 83.5±4.4 0.64 0.139 
Attention 56.0±15.9*
** 
56.8±10.4 53.3±11.3 0.09 0.546 
Delayed Memory 79.0±24.6 81.5±26.3 87.0±29.3 0.11 0.526 
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Figure 1. DST Score by Participant Over Time 
 
Note: Participants 1,2,3,4 diagnosed with ABI, remaining are diagnosed with PD 
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APPENDIX A: REVIEW OF LITERATURE 
I. Introduction 
Parkinson's disease (PD) and acquired brain injury (ABI) are unique 
neurological diagnoses that impact the brain and share common sequelae that affect 
nutritional status, cognition, and cardiometabolic risk.1-5 Parkinson’s disease is a 
neurodegenerative movement disorder.6 Traumatic brain injury (TBI) and stroke are 
two types of ABI that cause temporary or permanent damage to the brain.7 Currently, 
more than 2.5 million individuals have one of these neurological disorders.8-10 These 
conditions may decrease life expectancy by as much as 33 years compared to healthy 
populations, 11-13 and declines in functionality and health outcomes can reduce quality 
of life.14-16 These declines negatively impact nutritional status, cognition, and 
cardiometabolic risk earlier in life than that of the general population.7, 17 
Parkinson’s disease is currently the 14th leading cause of death for Americans 
and the number of diagnosed individuals is predicted to more than double in the next 
25 years.18, 19 Unintentional injuries such as TBI are currently the 4th leading cause of 
death for Americans with TBI-related emergency department visits increasing 70% in 
the past decade.10, 18, 19 Part of the increase in TBI prevalence may be due to the recent 
wars involving the United States (US) with Iraq and Afghanistan.20 Stroke rates have 
doubled in the past five years, making it the 5th leading cause of death for 
Americans.19, 21 These neurological disorders contribute to the significant cost of 
prescriptions, health care, and lost productivity.3, 14, 22 The total current annual 
economic impact of PD, TBI, and stroke in the US is $121.3 billion9, 14, 23 In the 
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future, these costs are expected to rise with the increase in incidence and prevalence of 
these neurological conditions.  
Routine, consistent monitoring of long-term nutritional status, cognition, and 
cardiometabolic risk factors in those with PD and ABI is lacking but critical to 
determine how these populations differ from those without these neurological 
conditions.2, 3, 5 Assessing the natural evolution of the disease process can indicate 
how nutritional status, cognition, and cardiometabolic risk change over time. Earlier 
and faster deteriorations in these areas can lead to chronic diseases such as 
cardiovascular disease (CVD) and can negatively influence quality of life sooner.15 
Knowledge of how and when these specific neurological disorders impact these health 
outcomes will allow for earlier and more targeted interventions to attenuate disease 
progression. With such little research being performed in these populations and the 
variability in individual outcomes, more knowledge on individual data and the 
evolution of the diseases will allow for detection of disease trends, and promote earlier 
and more targeted interventions to attenuate disease progression. 
II. Neurological Disorders 
a. Parkinson’s Disease: Definition and Description 
Parkinson’s disease is a neurodegenerative movement disorder.6 Up to 60,000 
new cases of PD are diagnosed each year in the US, adding to the 1 million people that 
were already living with the disease in 2014.8 While the exact etiology of PD remains 
unknown, the disease routinely presents itself in adults over the age of 60, with only 
4% of the cases occurring in those under the age of 50.24 Males have a significantly 
higher incidence rate of PD; 1.5 times greater than that of females (p=0.031).25 The 
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pathological trademark of PD is a lack of dopamine-producing neurons in the brain.26 
Since dopamine helps regulate body movement, lacking this critical neurotransmitter 
can cause uncontrollable tremor, postural imbalance, slowness of movement and 
rigidity, all of which are characteristic motor symptoms of PD.26 Life expectancy of 
those living with PD can be the same as the general population,27 and the disease can 
continue for upwards of 20 years or more once motor features manifest.28 Parkinson’s 
disease is chronic and progressive, and although not considered fatal, there is no 
current cure or treatment that successfully reverses the effects of the disease.8  While 
symptoms of PD gradually result in disability and impairment, a variety of tools have 
been created to help delay and prevent deterioration. 
Two rating scales are predominately used to characterize the disability and 
impairment level of individuals with PD. The Hoehn and Yahr scale focuses primarily 
on motor symptoms and is based on the level of clinical disability ranking stages 1 
through 5.8, 29 Stage 1 of the Hoehn and Yahr scale involves minimal or no functional 
impairment, while stage 5 involves severe disease progression with confinement to 
bed or wheelchair unless aided.29 A more recent and comprehensive scale called the 
Movement Disorder Society-United Parkinson’s Disease Rating Scale (MDS-UPDRS) 
is comprised of four sections that focus on both motor and non-motor symptoms; I: 
non-motor experiences of daily living; II: motor experiences of daily living; III: motor 
examination; and IV: motor complications.30 Each section is based on a five-point 
range of impairment and disability, where 0 = normal, and 4 = severe.30 Non-motor 
symptoms of PD include cognitive impairment, neuropsychological problems, sleep 
disturbances, sensory complaints, urinary and gastrointestinal problems, symptomatic 
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orthostasis, and fatigue.30 Both assessment scales are used routinely to delay or 
prevent disease progression in individuals with PD by assessing for symptoms that 
would suggest signs of decline. Disease advancement as measured on these scales can 
impact nutritional status, cognition, and cardiometabolic risk factors. 
 b. Traumatic Brain Injury: Definition and Description 
A TBI is a type of ABI that is a major cause of disability in the US.10 Although 
it is considered an acute injury, individuals can face a variety of chronic complications 
and life-long challenges in recovery.31 Traumatic brain injury occurs as a result of an 
external mechanical force such as a violent blow or jolt to the head or body which 
causes impairment of brain function.32 There are approximately 1.7 million new cases 
annually.10 Children aged 0 to 4 years, older adolescents aged 15 to 19 years, and 
adults aged 65 years and older are most likely to sustain a TBI.10 Rates of TBI are 
higher for males than for females, with approximately 1.4 times as many TBIs 
occurring among males than females.10 Falls are the leading cause of TBI, followed by 
motor-vehicle traffic injuries and striking injuries.10 Approximately half of individuals 
with a severe TBI will need surgery.33 
Symptoms and sequelae resulting from TBI are dependent on multiple 
variables including the timing of medical attention, severity and location of the injury, 
age, and general health of the individual at the time of injury.33 There is no current 
treatment to reverse the initial brain damage.31 Deficits resulting from a TBI are 
typically seen in cognition, emotional functioning, behavior, communication, sensory 
functioning, and mental health.31, 33 Traumatic brain injury can also lead to increased 
risk for other health conditions, such as depression, Alzheimer’s disease, and stroke.34-
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36 Depending on age of injury onset, it is estimated that the average length of survival 
for an individual after experiencing a TBI is 50 years.37 Life expectancy is reduced by 
approximately four years.13 Despite the fact that much has been learned about the 
effects of TBI on the brain in recent years, there has been no significant improvement 
in treatment due to the heterogeneity of the injuries and difficulty in identifying which 
individual are most likely to benefit from different forms of treatment.38 
Severity of TBI is typically measured using the Glascow Coma Scale (GCS), 
in which injuries are classified as mild, moderate, or severe according to initial level 
of consciousness after injury.39 Mild TBI may cause temporary dysfunction of brain 
cells, while severe TBI can result in permanent damage to the brain that can cause 
long-term complications or death.32 In an article reviewing the epidemiology and 
impact of TBI, Langlois, Rutland-Brown, and Wald40 issue a call to action to further 
quantify the increased risk of health problems, both short- and long-term after TBI. 
Specifically, the areas of nutritional status, cognition, and cardiometabolic risk factors 
requires additional investigation. 
c. Stroke: Definition and Description 
A stroke is a type of ABI that occurs when blood circulation to the brain fails, 
resulting in decreased blood and oxygen flow, and ultimately cell death.41 While an 
estimated 6.6 million Americans ≥ 20 years of age have already had a stroke, 795,000 
new strokes occur each year, 9 with the expectation of the number of new strokes to 
double over the next 40 years.9 Although stroke can occur at any age, prevalence is 
higher in older adults, with the risk of stroke doubling each decade after the age of 
55.41 African Americans have nearly twice the risk as Caucasians of having a first 
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stroke.41 Additional non-modifiable risk factors for stroke include family history and 
gender.9, 41 Annually, approximately 55,000 more females than males have a stroke.9 
Modifiable risk factors include cigarette smoking, physical inactivity, poor nutrition, 
heart disease, high blood pressure (BP), diabetes, dyslipidemia, lower levels of 
education, and living in the southeastern US.9 
Strokes are categorized by etiology and severity. Ischemic stroke accounts for 
approximately 80% of all strokes and are caused by a blockage of blood flow in the 
brain or neck.41 Hemorrhagic strokes account for the other 20% of strokes that are 
caused by bleeding into the brain.41 Severity of a stroke is typically measured using 
the National Institute of Health Stroke Scale (NIHSS), which provides a quantitative 
measure of stroke-related neurologic deficit.42, 43 The NIHSS is comprised of the 
following items; consciousness, language, neglect, visual-field loss, extraocular 
movement, motor strength, ataxia, dysarthria, and sensory loss. Each item score ranges 
from 0-4, with higher scores indicative of higher impairment. The item scores are 
summed for a patient's total NIHSS score.42, 43 
 Similar to TBI, symptoms and sequelae resulting from stroke are dependent on 
variables such as the timing of medical attention after the injury, severity and location 
of the stroke, age, and the general health of the individual at the time of the stroke.44 
Some individuals are able to make a full recovery after stroke, while others may live 
with lifelong consequences.41 After stroke, deficits are typically seen in cognitive, 
physical, and psychological functioning.4, 5, 45 Stroke can also lead to increased risk for 
other health conditions, such as CVD, recurrent stroke, depression, dementia, and 
Alzheimer’s disease.45-47 There is no current treatment to reverse the initial brain 
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damage done in stroke, and it is estimated that individuals with stroke live 33% fewer 
remaining years when compared to matched controls.11 This reduced life expectancy 
increases the importance of improving quality of life to make the remaining years of 
life meaningful. Health outcomes of importance include nutritional status, cognition, 
and cardiometabolic risk factors, with additional research needed to determine how 
these areas are affected post-stroke. 
While outcomes and life expectancy can vary between PD, TBI, and stroke, it 
is important to look at the three conditions together because they share common 
symptoms and sequelae impacting nutritional status, cognition, and cardiometabolic 
risk factors.7, 14, 48 For example, similar impacts on nutritional status can be the result 
of problems with chewing, swallowing, and motor skills that occur across all three 
disease states.49-51 In addition, cognitive deficits in the areas of attention and 
memory12, 17, 52, 53 and cardiometabolic risk factors such as hypertension1, 36, 48, 54, 55 
have been identified in all individuals post-diagnosis. A thorough understanding of the 
disease evolution on these health outcomes has yet to be established. Assessing and 
monitoring nutritional status, cognition, and cardiometabolic risk factors in these 
individuals can allow for the delineation of a timeline of decline and allow for 
comparisons to be made within groups. Routine monitoring of these health outcomes 
will greatly influence life post-diagnosis and allow for earlier and more targeted 
interventions to be developed to attenuate disease progression. 
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III. Nutritional Status in Individuals with Neurological Disorders 
 a. Defining Nutritional Status 
“Nutritional status” implies measurement of the responses to nutrients, or lack 
of nutrients, by an individual, a group, or a community.56 Nutritional status is often 
determined by screenings that identify individuals requiring a more thorough nutrition 
assessment due to identified possible nutrition risk which can then result in developing 
an intervention plan.57 There is currently no consensus on a definition of nutritional 
status or evaluation instrument for individuals with neurological disorders. A review 
of previously used tools to measure nutrition status in individuals with neurological 
disorders is presented in Table 1.  
Table 1: Comparison of Dietary Screening Tools 
 Mini-
Nutritional 
Assessment 
(MNA) 
 
Mini-
Nutritional 
Assessment 
Short-Form 
(MNA-SF) 
 
Dietary 
Screening 
Tool 
(DST) 
Subjective 
Global 
Assessment 
(SGA) 
Patient-Generated 
Subjective Global 
Assessment (PG-
SGA) 
Malnutrition 
Universal 
Screening 
Tool 
(MUST) 
 
Population Older 
adults 
Older adults 
(>65) 
 
Older 
adults 
 
Adults Malnutrition in 
oncology/chronic 
catabolic disease 
Adults 
 
Dietary Intake   X X X  
Weight History/Loss X X  X X X 
BMI X X    X 
Mobility/Function X X  X X  
Acute Disease X X   X X 
Physiological Stress X X     
Neuro-physiological 
Problems 
X X     
Physical Exams    X X  
Gastrointestinal 
Symptoms 
   X   
Symptoms Affecting Food 
Intake 
X X   X  
Metabolic Stress     X  
Mid-Arm Circumference 
(MAC) 
X      
 
For the most part, each tool has its own strengths and limitations. The Mini 
Nutrition Assessment (MNA)58, used more frequently in the literature, is a complex 
tool with 18 questions comprised of anthropometrics, a global assessment, a diet 
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questionnaire, and a subjective assessment. The MNA Short-Form (MNA-SF)59 is 
comprised of 6 of the original 18 questions and has been used less, possibly due to the 
fact that it was recently validated in 2009. Both tools have only been validated in older 
adults. The Subjective Global Assessment (SGA),60 comprised of a medical history 
and physical exam, and the Patient-Generated SGA (PG-SGA),61 an adaptation 
developed specifically for use in oncology, are both tools used less frequently in the 
literature. Despite their novelty, they are valuable for their comprehensive 
appreciation of nutritional and non-nutritional factors. The Malnutrition Universal 
Screening Tool (MUST)62 was created for use in all patients based on the unique 
variables of current weight status, unintentional weight loss, and presence of acute 
disease. The Dietary Screening Tool (DST)63, 64 determines nutrition risk by scoring 
questions that assess dietary quality, awarding more points for higher consumption of 
healthier foods and less points for consumption of less healthy foods. Regardless of 
each tools respected strengths and limitations, all tools can be useful to an extent for 
their ability to quickly identify those at risk- requiring nutrition assessments that 
provide more detailed information including diet history, weight changes, and a 
physical examination.57  
Tool selection is an important consideration when assessing an individual. For 
example, diet quality, which can be measured by the DST, is a potentially modifiable 
factor that has been associated with many chronic diseases.65 The negative outcomes 
associated with poor nutritional status are numerous,9, 66 and it is well established that 
diet plays a crucial role in cardiovascular health and CVD prevention.9, 67 Low quality 
dietary patterns are positively associated with chronic disease risks such as obesity, 
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metabolic syndrome, and CVD, while high quality diets have been inversely 
associated with major chronic disease.9 This tool can provide valuable knowledge on 
individuals with PD and ABI, as many exhibit compromised intakes of foods and 
nutrients that place them at nutrition risk without evidence of clinical malnutrition.64 
Measures of food intake and dietary quality can also help to provide insight into food 
behaviors describing habitual consumption details of areas that need improvement.   
For these reasons, the DST may be a more appropriate tool than others for 
individuals with cognitive deficits such as those with PD and ABI. The DST is brief, 
low participant burden, and relatively easy to complete. Those considered at risk using 
the DST may be recommended for a nutritional assessment that would necessitate 
interventions specifically aimed at improving dietary intake to improve overall 
nutrition status. Consistent assessments repeated over time could lead to a better 
understanding of the relationship between diet and disease.64 Therefore, analysis of 
dietary quality can be an important approach for early identification of those with 
compromised dietary intake, which may be indicated by a nutritional risk screening. 
Identification of these individuals can help guide individualized intervention 
development, directed toward preventing or diminishing the rate of decline. Proactive 
screening and intervention in older adults has proven successful as a public health 
strategy to improve dietary intake and quality of life, as well as for primary or 
secondary prevention of disease.68, 69 Similar effects can be expected with proactive 
screening of individuals with PD and ABI.  
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b. Nutritional Status of Individuals with PD 
Factors Affecting Nutritional Status in Individuals with PD 
Multiple functional changes occur in individuals with PD that affect nutritional 
status. PD is typically seen in the older population, and the mean age of diagnosis of 
PD is 62 years.70 Individuals with PD may be at greater risk for poor nutritional status 
compared to older adults without the disease due to simultaneous declines associated 
with aging and disease progression.71 These physiological changes include reductions 
in sense of smell and taste, decreased ability to chew and swallow, and alterations in 
gastrointestinal and bowel function.71-74 Possible nutritional complications resulting 
from PD include loss of appetite, unintentional weight loss, decreased enjoyment of 
food, alterations in nutrient needs, and ultimately deficits in overall nutritional status.75 
Changes in body composition like increases in adipose tissue and decreases in muscle 
mass, strength, and ability to perform activities of daily living are seen as people age 
and as a sequelae of PD.76-78 Furthermore, individuals with PD can display impaired 
motor skills hindering food shopping, cooking, and eating due to a reduced ability to 
safely prepare food, use utensils, and transfer food to the mouth.79-82 Combined with 
impaired cognition, these deficits can adversely affect nutritional status by altering 
dietary habits and food intake.80-82  
Physiological changes experienced by those with PD may be exacerbated by 
additional non-physiological changes. These can include an increase in the number of 
medical costs and hospital days.14 In addition, numerous costly pharmacologic 
medications prescribed for PD come along with negative side effects.14, 83 There is a 
significant financial burden placed on this population from costs related to disability, 
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therapy, and medicine.14 As a result, individuals with PD have twice the direct medical 
costs of those without PD.14 Medications for PD treatment including Levodopa, the 
most effective agent in the management of Parkinson’s symptoms, which can cause 
adverse side effects such as nausea, gastrointestinal distress, lack of appetite, 
confusion,  
and impulsive behaviors like binge eating.84 Medications for PD may also 
interact with certain foods, other medications, vitamins, herbal supplements, over the 
counter cold pills and other remedies. For example, Levodopa competes with protein 
for absorption from the gut.84 These non-physiological changes need to be taken into 
consideration when assessing nutritional status of individuals with PD, as they can 
play an important part in the alteration of dietary quality and intake. 
Additional complications from PD that can affect nutritional status are anxiety 
and depression.17, 83, 85 Approximately 35% of individuals exhibit clinically significant 
depressive symptoms while approximately 40% exhibit symptoms of anxiety.85, 86 
Disease progression can cause symptoms such as loss of independence and low self-
esteem by forcing individuals to make changes to their normal habits and routines.79 
Usual simple tasks such as grocery shopping and cooking meals can become stressful, 
difficult, and burdensome to accomplish as the disease progresses and as debilities 
such as hyperkinesia begin to appear.79 Ultimately, the entire eating experience can be 
affected, potentially causing nutritional needs to be unmet.79 If not treated in a timely 
manner, these psychiatric disorders can have significant influences on quality of life 
and nutritional status in individuals with PD.17, 79, 83, 85 
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Assessment of Nutritional Status in Individuals with PD 
Numerous studies have shown a relationship between nutritional status and 
PD, with a variety of different tools used in a variety of sub-populations.2, 48, 57, 87, 88 A 
commonly used tool in individuals with PD in the current literature is the MNA. Using 
the MNA, Barichella et al.88 reported malnutrition risk increased from 22.9% to 34.3% 
over three years in individuals with PD with a mean age of 70.5 ± 5.5 years and a 
mean disease duration of 9 ± 6.3 years.88 The MNA was also used by Vikadhl et al.81 
who found the risk of malnutrition increased from 14% to 20.7% from baseline to 
three years post-diagnosis in a group of individuals with PD with a mean age of 68.4 ± 
8.0 years, compared to an increase from 0% to 8.3% in matched controls. Such 
different percentages of malnutrition in similar populations using the same tool over 
the same amount of time could be the result of measuring at different times post-
diagnosis. Despite these differences, increases in risk of malnutrition in a timespan of 
just three years would suggest further deterioration in the future. Continuous 
monitoring of individuals is necessary in order to identify and/or prevent the 
development of later-onset complications. 
Another tool used in this population recently was the DST.48 Using a smaller 
sample with a disease duration of 5.28 ± 4.28 years, LoBuono et al.48 found that 38% 
of individuals with PD were at nutrition risk and 50% were at possible nutrition risk 
based on dietary quality criteria. However, this study only looked at one point in time 
and it has been suggested by Fereshtehnejada et al.87 that it is necessary to closely 
monitor and evaluate aspects of nutrition routinely over the long-term. There is a 
current lack of longitudinal research being done on individuals more than 12 months 
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post diagnosis, which is necessary to help better understand  not only what factors are 
influencing nutrition, but also how nutrition is influencing other health and lifestyle 
factors. 
c. Nutritional Status of Individuals with TBI 
Factors Affecting Nutritional Status in Individuals with TBI 
Similar to individuals with PD, individuals with TBI experience physiological 
sequelae that affect nutritional status including cognitive deficits, depression, 
alterations in gastrointestinal function, sleep disturbances, and impaired ability to 
shop, cook, and eat independently.16, 34 In addition, alterations in swallowing ability 
can impact the nutritional status of individuals with TBI.50 Impaired cognition and 
damage to the part of the brain that involves swallowing can contribute to dysphagia.50 
Dysphagia after TBI is reported to be as high as 61%, and up to 16% of individual do 
not regain independent oral feedings even 6 months post-injury.49 Additional 
complications that happen immediately after injury include dental and facial fractures 
and/or the need to be mechanically ventilated, which may eliminate an oral diet 
completely and require enteral or parenteral nutrition.89 Nutrition is a significant 
predictor of death in individuals with TBI.90 Early and adequate nutrition support 
immediately post-TBI is important and has been associated with a decrease in 
mortality rate,90 but little is known about the impact of nutrition after. In a review 
article of the long-term health implications of TBI, Murphy and Carmine16 emphasize 
the importance of consistent health screenings to evaluate the individuals 
comprehensive issues. Tools used at screenings that measure nutritional status are 
important to identify and/or prevent later-onset complications after injury.16 
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Assessment of Nutritional Status in Individuals with TBI 
Assessment of nutritional status during and immediately after the acute stages 
of TBI has been thoroughly examined, with a majority of data showing significant 
nutrition deficits during this time.49, 66, 91, 92 Data looking beyond the first few months 
post-diagnosis is limited. One of the few studies of the post-acute rehabilitation period 
was a retrospective study performed in Sweden assessing individuals with a severe 
TBI.49 Using the MUST, Krakau et al.49 found that 68% of individuals with TBI 
exhibited signs of malnutrition extending to the second month after injury. Even less 
data exists on nutritional status more than six months post-injury. Using the DST, 
LoBuono et al.48 assessed individuals with ABI who were 14.25 ± 5.6 months post-
injury and found 75% of individuals were at possible nutrition risk. It is unclear how 
nutritional status is affected over time once individuals are in the rehabilitation period, 
as consistent nutritional status assessments that occur a year or more post-diagnosis 
are difficult to find. 
 d. Nutritional Status of Individuals with Stroke 
Factors Affecting Nutritional Status in Individuals with Stroke 
Factors affecting nutritional status in individuals with stroke are similar to 
those of individuals with PD, since both conditions tend to occur at an older age. The 
average age of an individual experiencing a stroke is 69, only 4 years greater than the 
average age of an individual with PD.93 The risk of poor nutritional status after a 
stroke is increased for those that are older.91 There is a high level of impairment and 
disability immediately post-stroke due to brain trauma and as a result adequate 
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nutritional support can be difficult.94 Dietary intake is reduced immediately post-
stroke, during hospitalization and rehabilitation, and 6 months after diagnosis, 
resulting in energy and protein deficits associated with overall loss of body tissue.94  
Significant functional changes that present after stroke include dysphagia, 
aphasia, motor weakness, and disturbance of sensory function.4 These deficits can 
alter the ability of the individuals to prepare, shop, and cook food.4 Dysphagia is 
highly prevalent in individuals immediately post-stroke.95 According to a systematic 
review by Martino et al.95  dysphagia incidence has been reported as high as 78% 
depending on the instrument used. Dysphagia is a dangerous consequence of stroke 
that increases the risk of pneumonia, dehydration, and malnutrition (Figure A).96 
Individuals who are not diagnosed with dysphagia may still experience 
sequelae related to the stroke including poor appetite from motor weakness or sensory 
function disturbances.4, 97 As a result, they may eat more slowly or be less inclined to 
eat because of facial weakness or social embarrassment related to changes in eating 
skills; all of which will decrease total energy intake.97 Fatigue and low energy levels 
are a frequent burden in individuals after stroke recovery that can affect food 
purchase, preparation, and appetite.4, 98 Sequelae such as chronic fatigue can result in 
feelings of sadness and depression that can also affect nutritional status; 15% of 
individuals post-stroke report feeling gloomy and sad at least some of the time.4 An 
individual with these symptoms might experience a decrease in motivation to eat 
and/or difficulties with food preparation that cause them to reduce their intake.4 
Undernutrition immediately after a stroke increases the risk of poor outcomes such as 
reductions in functional status, prolonged hospital stay, and reduced survival-
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outcomes that can continue six months post-stroke and beyond.99-102 While 
individualized nutritional support can prevent clinically significant weight loss and 
improve quality of life three months after stroke in elderly individuals at nutritional 
risk, the long term effects of poor nutritional status and prevention efforts have yet to 
be studied.99 
Figure A: 
 
Assessment of Nutritional Status in Individuals with Stroke 
 The interaction of nutrition and stroke is well recognized, and variety of tools 
have been used to classify nutritional status after stroke.91, 94, 103 These tools can 
identify people who may be at nutritional risk. Based off the results of the tool, an 
intervention can be initiated to help improve nutrition, delay the effects of aging, and 
possibly reduce the burden of disease.103 The prevalence of poor nutritional status 
immediately post-stroke has been as high as 26.3%.104 Substantially less research 
exists on nutritional status after stroke hospitalization. Finestone et al.92 evaluated 
nutritional status using biochemical and anthropometric data to identify the presence 
of malnutrition. On admission to a stroke rehabilitation service immediately after 
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hospital discharge, 49% of individuals were considered malnourished, declining to 
34%, 22%, and 19% at 1 months, 2 months, and 4 months, respectfully.92 Brynningsen 
et al.102 evaluated nutritional status using the variables of body weight, BMI, mid 
upper arm circumference, tricep skinfold thickness, and serum concentrations of 
albumin and transferrin, with malnutrition being defined as the presence of two or 
more abnormal variables. One week after stroke, 35% of individuals studied were 
considered malnourished, with 22% being malnourished six months post-stroke. These 
results show that deficits are still seen in the population several months after the event, 
and warrants further investigation into whether deficits continue beyond this period of 
time. Furthermore, while these results provide important insight into the overall trends 
of nutritional status in the stroke population, we do not know how many individuals 
post-stroke improve, decline, or have no change in their nutritional status over time. 
The lack of research in this population on long-term nutritional status demonstrates the 
need for more knowledge in this area, so that prevention and intervention programs 
can be developed and implemented at the appropriate times. 
IV. Cognition in Individuals with Neurological Disorders 
 a. Defining Cognition 
Cognition is defined as conscious mental activities such as thinking, 
understanding, learning, and remembering.105 A gold standard cognition assessment 
tool has yet to be established, as different tools provide varying assessment 
measurements. For example, the SCales for Outcomes in PArkinson's 
disease‐COGnition (SCOPA‐COG)106 was developed specifically for individuals with 
PD for the purpose of comparing groups in research settings and not as a screening or 
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diagnostic tool, with indexes for attention, memory and learning, executive functions, 
visuospatial functions, verbal functions, and thinking and reasoning. The Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS)107 was developed 
for the dual purposes of identifying and characterizing abnormal cognitive decline in 
the older adult and as a neuropsychological screening battery for younger individual 
with indexes for immediate memory, visuospatial/constructional, language, attention, 
and delayed memory. Repeated measurements of cognitive status over time is vital in 
individuals with PD and ABI in order to prevent, detect, and monitor cognitive 
deficits. 
b. Cognition in Individuals with PD 
Although PD is primarily characterized as a movement disorder, deficits in 
cognition are also associated with the disease and can greatly impact activities of daily 
living. Impairments in cognition are common even in newly diagnosed individuals, 
with worsening levels associated with the duration of the disease.3, 12, 106, 108 It appears 
that there is a spectrum of cognitive impairment, ranging from a lesser severe form 
known as mild cognitive impairment (MCI), to PD dementia (PDD).109 
Cognitive deficits in this population are seen in a variety of domains, including 
attention, memory and learning, executive functions, visuospatial functions, verbal 
functions, and thinking and reasoning.106 Risk factors for MCI in individuals with PD 
are older age at disease onset, male gender, severity of motor symptoms, and advanced 
diseased stage.110 Individuals with PD with MCI have an increased risk of developing 
dementia, both in general and when compared to individuals with PD with intact 
cognition.3, 111 Thus, it has been suggested that MCI in PD is an early manifestation of 
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dementia.111, 112 Mild cognitive impairment is defined as the transitional state between 
normality and dementia, with cognitive impairment that is abnormal for age but with 
little to no impairments in activities of daily living.111, 112 Aarsland et al.113 found that 
for individuals with PD, the cumulative incidence of dementia was 52% four years 
after diagnosis and nearly 80% after eight years. 
Changes within the brain are the source of cognitive deficits seen in 
individuals with PD.26, 114 The cause appears to be the lack of dopamine-producing 
neurons, but the exact mechanism responsible for cell death remains unknown.26 
Research suggests that the pathogenic trigger could actually be a collection of causes 
or events, that although harmless when appearing by themselves, may produce 
deleterious effects upon accumulation.26 Cumulatively, mitochondrial dysfunction, 
oxidative stress, and altered expression of proteins are thought to play a critical role in 
the pathogenesis of PD, and it is hypothesized that these processes are induced by non-
genetic factors such as environmental toxins in interaction with susceptibility 
genes.114, 115 
Cognitive deficits in individuals with PD are heterogeneous, seen in a variety 
of domains, and at different stages of PD.116 Deficits in executive function tend to be 
the most frequently reported cognitive problem.116 These deficits affect the ability to 
plan, organize, and regulate goal-oriented behavior. Using the Frontal Assessment 
Battery (FAB) to measure executive functioning, Lima et al.117 found that even after 
controlling for age and education level, individuals with PD had significantly lower 
scores than controls (13.7 vs. 14.9; p < 0.0001). Consistent with these results are those 
of Verbaan et al.,118 who found that individuals with PD scored significantly lower on 
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all cognitive subdomains using the SCOPA‐COG compared with controls, with the 
largest differences occurring in the subdomains of executive functioning and memory. 
Furthermore, memory, attention and visuospatial functioning are also considered 
important domains that see decline in individuals with PD.106, 108-111, 116, 118 In 
comparison with controls, Verbaan et al.118 found that all four cognitive domains were 
impaired in individuals with PD. Cognitive deficits are closely associated with 
depression in individuals with PD and can negatively affect quality of life.17, 79 
c. Cognition in Individuals with TBI 
Cognitive deficits are seen in virtually all individuals who sustain a TBI, as the 
injury directly impacts the brain.53, 119 These cognitive deficits often become chronic, 
negatively affecting nutrition and overall health status by directly impacting the 
activities of daily living. Impairments in cognition are most prominent in newly 
diagnosed individuals, with improvements occurring during the rehabilitation 
period.119 While there is insufficient evidence to determine whether mild TBI is 
associated with cognitive deficits six months or longer post-injury, cognitive deficits 
are associated with penetrating, moderate, and severe TBIs in individuals who are six 
months or more post-injury.53 
There is significant variability in cognitive status after TBI, given wide 
heterogeneity among individuals.5, 119 Chronic cognitive sequelae that occur after TBI 
include problems with attention, memory, problem solving, judgment, new learning, 
and processing speed.119 While the specific areas of cognition affected by TBI have 
been studied extensively, there is a lack of evidence on the timeline of recovery of 
cognitive status in individuals from the community.48, 119 Millis et al.119 looked at 
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neuropsychological status of individuals with TBI at one year and five years post-
injury, finding 22% improved and 15% declined. It appears that improvements in the 
areas of attention, cognitive speed, verbal fluency, verbal memory, and 
visuoconstruction continue up to around 18 months post-injury, while long-term 
deficits are more likely to be seen in the areas of memory function, attention, and 
processing speed.119 Additional population-based studies are required to reliably 
identify the individuals at risk for cognitive decline, as determinants of progression of 
cognitive impairment are still unknown. 
 Individuals with TBI demonstrate short-term and long-term 
neuropsychological deficits.34, 35, 120, 121 Short-term effects have been extensively 
studied, including reduced capacity for new learning and slowed information 
processing.120, 121 Depression has been seen across the traumatic brain injury timeline. 
There is an increased risk of depression following head injury, while injury during 
early adulthood has been associated with a lifetime prevalence of minor and major 
depression.34 Furthermore, research suggests individuals with TBI have an increased 
risk of Alzheimer’s disease and other forms of dementia years after initial injury.35 
Similar to what is seen in the PD population, cognitive deficits including 
neurophysiological outcomes such as depression in individuals with TBI are closely 
associated with quality of life and increase the burden of illness, which may 
significantly affect overall health as a result.34  
d. Cognition in Individuals with Stroke 
Deficits in cognition are commonly associated with stroke and vary depending 
on the stroke severity.122 Similar to individuals with TBI, impairments in cognition are 
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most prominent in newly diagnosed individuals, with improvements occurring during 
the rehabilitation period.123 While some cognitive improvements do occur as 
individual progress after stroke, a majority continue with some degree of cognitive 
dysfunction.52 This chronic deficit in cognition can negatively influence nutrition and 
overall health status by directly impacting functionality.124 Recovery of cognitive 
function has been found to be a near-significant factor for return to work.52 In a study 
of 58 individuals age 65 and younger, Hofgren et al.52 found that despite significant 
improvements from discharge to one year, 83% still had cognitive dysfunction. Only 
7% had returned to work at one year, with this number improving to 20% after three 
years.  
Cognitive deficits in this population are seen in a variety of domains, including 
memory, orientation, language, and attention.122, 125 The risk and severity of cognitive 
deficits post-stroke do not appear to be influenced by the type of stroke,122, 125 but 
more influenced by age, mental decline before stroke, number of prescribed drugs, 
diastolic BP on admission, and episodes of hypotension during hospital admission.5 
Cognitive recovery in stroke is similar to that of TBI as it is highly dependent on a 
number of individual variables.5, 52, 123 As a result, it has yet to be determined who is 
more prone to deterioration.5 
While it appears that cognitive deficits remain permanent and fairly stable over 
the long term, more individuals tend to deteriorate than improve.5, 123 Using the 
Clinical Dementia Rating (CDR) to define progression of cognitive impairment, Del 
Ser et al.5 found that cognition remained stable for two years after stroke in 78.2% of 
193 individuals studied, while 14% declined and 7.8% improved. Using the Mini-
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Mental State Examination (MMSE),126 Patel et al.123 found similar results in that 
cognitive impairment remained highly prevalent up to three years post-stroke in 163 
individuals. At three months, one, two and three years post-stroke, the prevalence rates 
of cognitive impairment were 39%, 35%, 30% and 32% respectively. More specific 
longitudinal research extending beyond three years after stroke is limited. Consistent, 
long-term monitoring of cognitive status is needed to reliably identify and intervene in 
individuals at risk for cognitive decline. 
Similar to individuals with PD, individuals post-stroke have an increased risk 
of developing dementia, with approximately 1/6 of individuals having dementia before 
the stroke event.127 The risk of dementia is higher in older individuals and in those 
with preexisting cognitive deficits.127 Approximately 30% of survivors develop post-
stroke dementia (PSD) within 12 months of having a stroke, while many others 
experience indications of early cognitive impairment in the absence of dementia.125 
Cognitive Impairment, No Dementia (CIND) utilizes a combination of clinical and 
global cognitive criteria to identify cognitive impairment in the absence of 
dementia.128 Stephens et al.129 found that individual three months post-stroke with 
CIND were impaired in all cognitive domains, but scored significantly lower on tests 
of executive function, memory, and language compared to those not meeting CIND 
criteria. Deficits were significantly more pronounced in those with dementia in the 
areas of orientation and memory.129 It remains unknown whether CIND is the 
precursor to post-stroke dementia, and further research is required to establish if CIND 
can predict the possibility of further decline toward dementia.129 Understanding the 
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evolution of cognitive decline in individuals post-stroke and identifying individuals at 
risk could help to guide intervention development and improve overall quality of life. 
III. Cardiometabolic Risk Factors in Individuals with Neurological Disorders 
 a. Defining Cardiometabolic Risk Factors 
 The assessment of cardiometabolic risk factors is useful across diagnoses to 
guide treatment. Although CVD is the number one cause of death in the US, few 
studies have explored cardiometabolic changes in individuals with PD and ABI.19 
Cardiometabolic risk factors contribute to an increased risk for CVD and modifiable 
factors include: overweight/obesity, insulin resistance, hyperglycemia, dyslipidemia, 
hypertension, inflammation, smoking, and physical inactivity (Figure B).130 Non-
modifiable risk factors are age, sex, ethnicity, and family history.  
Figure B: 
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b. Cardiometabolic Risk Factors in Individuals with PD 
Current research demonstrates that those with PD may be at decreased CVD 
risk because of a decrease in sympathetic activity that reduces important 
cardiometabolic risk factors such as hypertension, diabetes, and dyslipidemia.131 This 
is because the sympathetic nervous system is involved in the release of cortisol and 
catecholamines, which through a variety of steps stimulates glycogenolysis and thus 
increases plasma glucose and lipids.131, 132 In addition, increased sympathetic activity 
has also been shown to increase blood pressure.132  However, many individuals with 
PD receive treatment that may negate any CVD risk reduction benefits.133 Levodopa, 
for example, raises levels of homocysteine in the blood.133 Elevated homocysteine 
levels have been associated with an increased risk of vascular diseases in both the 
general population and in those with PD.133, 134 Despite this association, several studies 
have demonstrated that the presence of hypertension is similar or lower in individuals 
with PD than controls.1, 131, 135 Although two of three studies had control groups that 
would not be considered representative of the general population, there may be other 
unknown factors involved that contribute to this occurrence.1, 135 While diabetes has 
been associated with chronic neurodegeneration and it is hypothesized that chronic 
hyperglycemia may exacerbate the severity of the motor disability136, 137, evidence 
associating diabetes and PD is inconclusive. 
When looking at individuals with PD, both weight loss and gain are seen over 
time.80, 138, 139 In general, individuals with PD tend to lose weight and be underweight, 
and PD has been reported as an independent risk factor for being underweight and 
experiencing weight loss.140 Beyer et al.138 found that individuals with PD were four 
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times more likely to report weight loss greater than 10 pounds than matched control 
subjects, and individuals with PD reported a mean weight loss of 7.2 pounds compared 
to 2.1 pounds in control subjects. Furthermore, Abbott et al.80 found that 29% of 
individuals with PD had a BMI <20 kg/m2 , compared with only 7% of a matched 
control group, and that 58% of individuals with PD had lost weight since onset of the 
disease. Strikingly, this study reported that almost 15% of individuals studied lost 
more than 20% of their original body weight, with none of the individuals starting 
with a BMI >27kg/m2. Since analysis of dietary intake has indicated that neither 
protein nor energy intake of individuals with PD significantly differ from the 
recommended values, it is hypothesized that weight loss is attributed to increased 
requirements or energy expenditure rather than reduced food intake.80, 141 Although 
studies show that individuals with PD often experience unintentional weight loss, less 
knowledge exists on when during the course of the disease this actually begins to 
occur. To our knowledge, the only current proposed outline of the possible natural 
history of body weight changes in individuals with PD can be seen in Figure C.2  
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Figure C: 
While a large portion of the research demonstrates individuals with PD lose 
weight, there is also data to show that some individuals gain weight after diagnosis.81, 
139 Vikdahl et al.81 performed a community based case-control study in individuals 
with PD with a mean age of 68.4 ± 8.0 years. Individuals with PD gained a significant 
amount of weight three years post-diagnosis (1.62 ± 4.60 kilograms (kg), p=0.009). 
Controls did not experience significant weight gain in the same time period (0.23 ± 
3.08 kg, p=0.724). Barichella et al.139 found 62% of 134 individuals with PD with a 
mean age of 65.9 ± 8.9 years and a mean disease duration of 10.6 ± 5.3 years were 
overweight or obese, with a higher proportion of obese individuals living with PD than 
in the general Italian population (25% vs 14%).  
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Weight gain has been reported after deep brain stimulation (DBS), a surgical 
procedure used in treatment of PD.142 Barichella et al.142 found that significant weight 
gain (14.8 ± 9.8% of original body weight) occurred one year after the procedure in 29 
out of 30 individuals studied. It is clear that weight shifts occur during the course of 
the disease, with both weight loss and weight gain being observed. Overall, weight 
loss has been more frequently observed as a continuous process that worsens as the 
disease progresses, with weight loss actually starting several years before diagnosis 
(Figure C).2, 141 Weight gain appears to be more of a result of surgical treatment 
procedures and has not been associated with the overt disease progression. 
Cereda et al.1 found that individuals with PD had a more favorable 
cardiometabolic risk profile when compared to a control group. In individuals in the 
early stages of PD, mean concentrations of glucose, total cholesterol (TC), and 
triglycerides (TAG) along with BP were all found to be lower in the individuals with 
PD.1 While mean concentrations of low density lipoprotein cholesterol (LDL-C) were 
still suboptimal in the PD population (113.0 ± 30), previous research has associated 
lower levels of LDL-C with PD.143 This study came with a large limitation in that 
controls were recruited from a medical center treating excessive body weight, and all 
were sedentary and obese. Furthermore, 25% of the control participants smokers. 
Studies looking at cardiometabolic risk factors over the long-term are lacking, but are 
necessary for the prevention of CVD in individuals with PD. Other neurological 
disorders, including TBI and stroke, also require further assessment of 
cardiometabolic risk factors in order to identify which risk factors are most prominent 
and therefore most necessary to screen for. 
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c. Cardiometabolic Risk Factors in Individuals with TBI 
Experiencing a TBI can effect multiple organ systems and cardiometabolic risk 
factors, initiating and accelerating the chronic disease process.144 In an article on the 
classification of TBI as a chronic process, not an event, Masel and DeWitt144 
encourage an emphasis on the management of TBI as a chronic disease and for it to be 
defined as such by health care and insurance providers. Current treatment with acute 
rehabilitation creates the perception that little additional treatment is needed and that 
no chronic effects exist. This misunderstanding can leave health deficits undetected 
and can increase the risk for health problems such as metabolic syndrome and CVD.16 
Individuals with TBI are slightly more likely to be diagnosed with traditional 
cardiometabolic risk factors before or after a TBI compared with unaffected 
individuals.55 Individuals with TBI had significantly higher rates of hypertension, 
diabetes, and CVD compared to unaffected individuals (16.4% vs 14.3%, 8.8% vs. 
7.0%, 9.6% vs. 8.1%), but similar rates of dyslipidemia (7.6 vs. 7.7%).55 These results 
have important clinical implications in the management of individuals post-TBI 
because they demonstrate that more intensive medical monitoring, support, and 
interventions are needed.55  
Weight gain in individuals with TBI may also increase the risk for CVD if 
additional risk factors are present.16 It has been noted that individuals with TBI have 
prominent risk factors for metabolic syndrome, a chronic medical disorder that 
increases the risk for both CVD and diabetes.16 Cardiovascular disease is considered to 
be the primary clinical outcome of metabolic syndrome, characterized by 
measurements of waist circumference, insulin resistance, elevated BP, and 
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dyslipidemia.145 Metabolic syndrome has overlapping risk factors with that of CVD, 
and both can be deadly if not treated appropriately.145 
Chronic TBI sequelae that could affect cardiovascular health include 
impulsivity, problems with memory, poor self-regulation, decreased mobility, altered 
sense of satiety, and prolonged use of anti-psychotic, anti-convulsant, and selective 
serotonin reuptake inhibitor medications.16, 50, 55 Currently, there is a knowledge gap 
on the status of blood pressure, the lipid profile, and blood glucose levels in 
individuals post-TBI. Knowledge of how and when cardiometabolic risk factors are 
affected by a TBI may help to prevent risk factors from occurring in the first place and 
treat risk factors that are already present. 
Weight status of individuals with TBI varies depending on the severity of the 
injury and the time since diagnosis. Individuals sustaining a TBI lose weight 
immediately after and approximately 1-2 months after injury, followed by a slow 
return toward the initial weight.49 Considerable metabolic alterations including 
hypercatabolism and hypermetabolism dramatically increase the demand for energy 
and protein immediately after injury.89, 146 Initial dramatic metabolic responses to 
trauma and escalation in nutritional demand typically results in weight loss in 
individuals with TBI.49 Using indirect calorimetry, Bruder et al.147 measured energy 
expenditure in individuals after severe TBI and found that expenditure increased to 
150% of basal energy expenditure 12 hours after lifting sedation. After sedation was 
lifted for 48 hours, energy expenditure remained elevated to 130% of basal energy 
expenditure.147 Overall, energy expenditure increased approximately 700 additional 
calories per day from the period during sedation to the time period off sedation.147 
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Krakau et al.49 assessed weight status of 56 individuals with TBI during the intensive 
care period, and found that within 3 ± 2.9 days of the first recorded measurement, all 
but four had experienced some initial weight loss.  
If individuals with TBI gain weight, it is common to be a later-onset 
complication more frequently associated with post-traumatic hypopituitarism 
(PTHP).148 Functionality of the pituitary gland, which sits at the base of the skull, is 
altered in individuals after TBI, reducing the amount of hormones normally produced 
by the gland.148 The prevalence of PTHP has been estimated at 16% in individuals >12 
months post-injury, with likelihood of PTHP increasing with severity of injury.149 
Posttraumatic hypopituitarism has been associated with an unfavorable body 
composition, lipid profile, and decreased quality of life.150 
Individuals with TBI and PTHP present with a less favorable cardiometabolic 
profile than those with TBI and without PTHP.148, 149 Prodam et al.151 reported higher 
prevalence of dyslipidemia and altered glucose metabolism in those with PTHP 
compared to non PTHP individuals >12 months post-injury. Triglycerides were 
significantly higher in individuals with PTHP than not (161.3 ± 29.3 vs. 98.0 ± 16.8 
mg/dL, p<0.05). Although TC levels did not significantly differ between the groups, 
the mean TC of individuals with PTHP was above the optimal concentration of 200 
mg/dL (204.1 ± 14.5 mg/dL). Agha et al.152 reported 13 of 50 individuals studied in 
the immediate period following TBI had diabetes, with nine individuals fully 
recovered by six months and one additional individual recovered by 12 months. While 
most cases of diabetes appear to recover completely, there are individuals who 
experience long-term diabetes who require chronic treatment. Although these 
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cardiometabolic risk factors have been assessed at the time of diagnosis and in the 
time period immediately after diagnosis, little has been done to monitor their 
progression over time in individuals living with TBI. Consistent, long-term monitoring 
of cardiometabolic risk factors is necessary to identify and/or prevent the development 
of later-onset complications for those that are obligated to live with the sequelae of 
TBI for years and even decades post-diagnosis with no true cure.  
d. Cardiometabolic Risk Factors in Individuals with Stroke 
In the US, approximately 185,000 individuals experience recurrent strokes 
annually, and they are associated with having a greater number of cardiometabolic risk 
factors.9 Survivors beyond one year die at twice the expected rate among the general 
population over the subsequent four years, and the most common cause of death is 
CVD.153 Therefore, identifying cardiometabolic risk factors in individuals after stroke 
can help mitigate this risk.154 Research performed on cardiometabolic risk factors 
following a stroke demonstrate the need for improvement in the management of 
secondary prevention strategies of cardiometabolic risk factors.155, 156 
Hypertension is an influential risk factor for cardiovascular events, and lower 
rates of recurrent stroke have been associated with lower BP.157 While it has been 
reported that each 10 mmHg increase in DBP increases the risk of first stroke by 
50%,158 decreasing DBP by 5 mmHg can reduce the risk of recurrent stroke by 1/3.159 
Although a target BP range has not yet been established, The Secondary Prevention of 
Small Subcortical Strokes multi-center international trial showed that recurrent stroke 
was reduced by 20% (p=0.07) in those at a goal SBP of <130 mmHg relative to those 
at a goal >130 mmHg.157 These reductions were statistically non-significant, but the 
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trends are clinically important in that they demonstrate that reduced blood pressure 
could reduce recurrent cardiovascular events.157 
Blood pressure, hyperlipidemia, and diabetes are among the risk factors that 
are often suboptimally managed after stroke.155 Mouradian et al.155 found that 1/3 of 
individuals post-stroke had inadequately managed BP at baseline and 14% at one year 
follow up, indicating suboptimal secondary prevention. Over 80% of individuals were 
inadequately managed for hyperlipidemia at baseline, with 51% remaining 
inadequately managed after one year. In 77% of diabetic individuals post-stroke, 
baseline glycemic control was considered inadequate. At one year post-stroke, 65% of 
diabetics continued to have inadequate glycemic control.155 These results of 
suboptimal management of multiple cardiometabolic risk factors post-stroke 
demonstrate the need for more consistent assessments and monitoring this population 
in order to prevent future damage from occurring and to make a significant impact on 
reducing the risk of CVD.  
Obesity is an important risk factor for stroke, and elevated BMI at the time of 
stroke is associated with poor outcomes including a lower likelihood of hospital 
discharge and extended hospital stay.160 After stroke, weight loss is seen as a result of 
sequelae such as eating difficulties and loss of independence.161 Weight loss >3 kg 
was found in 24% of individuals four months post-stroke and in 26% of individuals 
one year post-stroke by Jonsson et al.161 Weight loss is also brought about by the 
impaired metabolic signaling affected by stroke.162 A catabolic/anabolic imbalance 
may develop and result in wasting of fat, muscle, and eventually weight loss.  
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Due to the false alterations in plasma lipid concentrations immediately after 
stroke, it is recommended that lipid measurements should be taken at least three 
months after stroke.163 Ryder et al.164 found that TC (p=< 0.001), LDL-C (p=<0.001), 
high density lipoprotein cholesterol (HDL-C) (p=<0.01), and glucose (p=<0.001) 
concentrations all showed significant declines between days one and nine post-stroke, 
with TAG concentrations unchanged. No overall significant differences were seen 
between plasma lipid concentrations measured during the first 48 hours after stroke 
and those measured three months later, and more individuals had 
hypercholesterolemia in the first 48 hours than at three months. In a review that 
characterizes lipid profile changes after stroke, Rosenson et al.165 found maximal 
reductions in TC occur at days four to five post-stroke, with levels 47% below 
baseline. Both LDL-C and HDL-C concentrations decreased to 48% and 32% below 
baseline on day 7, respectively. In contrast to results from Ryder et al.164 TAG 
concentrations increased up to 58% above baseline on day seven.  
Reasons for differences in plasma lipid concentrations post-stroke can be a 
result of different stroke subtypes and stroke severity.54 When looking at the three 
subtypes of cerebral infarction, lacunar infarction, and intracerebral hemorrhage, Woo 
et al.54 found that individual suffering cerebral infarction had significantly higher 
concentrations of TC and LDL-C and significantly lower concentrations of TAG <48 
hours after stroke than 3 months later. The plasma lipid concentrations of individuals 
suffering lacunar infarction were similar on both occasions except for significant 
differences in higher TC and LDL-C <48 hours after stroke. No significant changes 
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were observed among individual suffering from cerebral hemorrhage except for a 
significantly higher concentration of HDL-C <48 hours after stroke.  
VI. Conclusion 
Parkinson’s disease, TBI, and stroke are three related neurological disorders 
that impact nutritional status, cognition, and cardiometabolic risk factors. Current 
research does not adequately address how natural disease evolution affects these three 
health outcomes in those living with these neurological disorders for twelve or more 
months post-diagnosis. Awareness to this gap in knowledge has been called to 
attention in all three disease states. Fereshtehnejad et al.87 stated, “a follow-up 
examination of PD patients to track longitudinal changes is of great demand,” while 
Masel and DeWitt144 recommended that TBI research be directed at discovering 
therapies to interrupt the disease processes after the initiating event as early as 
possible. Levine et al.166 concluded that stroke survivors warrant monitoring for 
impairment over the years after the event, and that strategies and systems will need to 
be developed in order to manage the long-term needs of this population. Further 
evaluation is required to understand the difference between each disease state and to 
improve treatment for those living with these long-term conditions. Further research is 
also required to determine differences in the rate of change in nutritional status over 
time between PD and ABI, as well as the impact of nutritional status on cognition and 
cardiometabolic risk factors over time.  
 Nutritional status, cognition, and cardiometabolic risk may change over time 
in individuals with PD and ABI. Repeated evaluations may increase awareness and 
knowledge of associated health risks, allowing for superior evidence-based treatments 
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and improved overall outcomes. Therefore, it is critical to perform consistent, long-
term evaluations of individuals with PD and ABI to detect disease progression trends 
and promote earlier and more targeted interventions to attenuate disease advancement. 
Consistent assessments over time of these health outcomes are vital in order to identify 
and/or prevent the development of later-onset complications. Furthermore, 
longitudinal assessments can help identify which consequences of these neurological 
disorders are most prominent and who is at greatest risk. 
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APPENDIX B: EXTENDED METHODOLOGY 
Subjects 
Individuals diagnosed with PD or ABI were recruited on a rolling basis starting 
in the fall of 2013. A total of thirteen participants were included in this study and 
consisted of nine males and four females between the ages of 33 and 71. Participants 
were eligible if they were between the ages of 18 to 85 and were diagnosed with PD, 
TBI, or stroke for > 12 months. Participants were required to have a method of 
transportation to the URI Walter J. Beaupre Speech and Hearing Clinic. This research 
was conducted as an ancillary portion of a longitudinal, observational study examining 
the physical, cognitive-linguistic, and dietary characteristics of individuals with PD 
and ABI. Approval was obtained from URI’s Institutional Review Board (IRB), 
Longitudinal Study of Communication, Nutrition and Physical Activity, IRB HU1314-
006.  
Participants were recruited via announcements, brochures, and word-of-mouth. 
Brochures were given to physician offices, hospitals, rehabilitation centers, and health 
professionals for recruitment. Individuals participating in URI’s Department of 
Communicative Disorder’s LOUD Crowd and Gateway Wellness Café also received 
brochures. Study staff explained the research project to potential participants. If a 
potential participant was interested and eligible to participate, they signed two copies 
of an informed consent form. The total time commitment for participants is 
approximately 3 hours for each evaluation for a total of 33 hours over 5 years. 
Participants were assigned identification numbers for data management that did not 
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include any identifying numbers or letters. Written data was stored in a locked file 
cabinet in 203 Fernwood on the URI campus. Electronic data with identified 
information was stored on a computer in 203 Fernwood and password protected and 
encrypted. De-identified data sets (identifying information like name, address, e-mail, 
and telephone numbers removed) were stored on password - protected computers in 
Fogarty 225 (Lofgren’s lab). 
Protocol Overview 
Participants came to the Walter J. Beaupre Speech and Hearing Clinic for 
anthropometric, biochemical, clinical, nutrition, and cognition assessments once every 
six months. Participants who have completed three time points will be assessed in this 
study. Participants fasted for at least 12-hours before each assessment, but were 
encouraged to drink water and stay adequately hydrated. At each assessment, a 12-
hour fasting blood sample was collected first followed by a blood pressure 
measurement. Specific assessments for this study include: nutritional status measured 
using the Dietary Screening Tool (DST), cognition measured using the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS), and 
cardiometabolic risk factors measured using anthropometric, biochemical, and clinical 
measurements. Descriptions of these and additional assessments are as follows. 
Assessments 
Nutritional Status 
 Nutritional status was assessed using the DST.1 The survey takes 
approximately 10-15 minutes to administer. The DST has been validated in older 
adults, and has not yet been validated in individuals living with neurological 
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disorders.1 The DST identifies dietary patterns and nutritional risk using a 25-item 
questionnaire. Seventeen questions relate to the frequency of intake of foods (e.g. how 
often do you usually eat fruit as a snack?). Two questions are behavior-related (e.g. 
how many different vegetable servings do you usually have at your main meal of the 
day?). One final question asks about the use of a multivitamin.1 The four questions 
answered either yes or no (e.g. do you usually add butter or margarine to foods like 
bread, rolls, or biscuits?) are not included in the principal component analysis (PCA) 
because of the dichotomous response options.1, 2 
Points are first based on major dietary category.1 For example, 15 points alone 
are allotted to two questions about vegetables.1 Answers to the questions are given 
points based on the chosen response. Point values are assigned based on higher 
consumption of a healthier diet.1 Eating three more servings of different vegetables at 
the main meal of the day is awarded seven points, while no vegetable servings at the 
main meal of the day is given a point value of zero.2 Questions dealing with less 
healthy patterns receive higher points for lower reported intake.1 For example, eating 
less ice cream is associated with more points received.3 One point is awarded to each 
of the yes-or-no questions, and five additional bonus points are available for the use of 
a multivitamin.1 To make the scores more clinically relevant and easily interpretable, a 
total point score of 100 was chosen.1 
Based on the DST score, participants are put into one of three risk categories.  
Individuals with scores of <60 are considered “at risk”.1 Scores of 60-75 are 
considered “possible risk” and scores >75 are “not at risk”.1 The DST has proven 
sensitivity, specificity, and positive predictive values when compared with nutritional 
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risk based on the Dietary Reference Intakes.1 The DST has been validated to identify 
nutritional risk in older adults when compared to 24-hour food recalls.2 
Cognition 
Cognition was assessed using the RBANS.4 The test takes approximately 30 
minutes to complete and was validated in adults ages 20-89.4 The RBANS is a 
measurement of neuropsychological status that includes 12 subtests, with five index 
scores for immediate memory, visuospatial/constructional, language, attention, and 
delayed memory. Each of the five index scores are added together for a total score; 
Scores are based on a standardized mean by age and education level for normative 
samples of 100±15, with lower scores indicative of greater cognitive impairment. The 
RBANS was originally designed as a screening tool to assess for dementia and has 
been validated as a reliable tool to assess the cognitive function in individuals with 
TBI and PD.5, 6  
Cardiometabolic Risk Factors 
Cardiometabolic risk factors assessed in this study were the anthropometric, 
biochemical, and clinical modifiable risk factors identified by the American Diabetes 
Association and the American College of Cardiology Foundation in the concept of 
global cardiometabolic risk.7-10 This concept represents the overall risk of developing 
CVD. Risk factor categories were: 1.) anthropometric (BMI)  2.) biochemical (TC, 
HDL-C, LDL-C, TAG, and glucose) and 3.) clinical (blood pressure). Risk criteria 
values can be seen in Table 1.  
 Anthropometric Biochemical Clinical 
 BMI TC HDL-C LDL-C TAG Glucose BP 
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Table 1: Criteria for Cardiometabolic Risk Factors7-10 
 
Anthropometrics 
Trained study personnel obtained all measurements using standard procedures. 
Height (cm) was measured using a stadiometer (Webb City, MO, USA). Weight (kg) 
was measured using a bioelectrical impedance analysis device (Tanita BF-556, 
Arlington Heights, Illinois). Height was rounded to the nearest 0.5 cm, weight was 
rounded to the closest 0.1 kg, and both were used to calculate BMI (kg/m2). Body 
mass index was classified according to predetermined categories: underweight <18.5 
kg/m2, normal weight = 18.5-24.9 kg/m2, overweight = 25-29.9 kg/m2, and obese ≥ 30 
kg/m2.11  
Biochemical  
Biochemical assessments of serum TC, LDL-C, HDL-C, TAG were performed 
to analyze cardiometabolic risk factors. Following a 12-hour fast, a finger stick was 
peformed and analyzed using the portable Cholestech® machine (Cholestech® LDX 
system, Hayward California). The Cholestech® table top analyzer is a valid and 
reliable method of analyzing lipid and glucose concentrations when compared to 
standard venous measures.12, 13 Using universal precautions and standardized 
techniques, study staff used a lancet and capillary tube to put forty microliters of blood 
from each participant’s finger into a cartridge for assay. Values used for cutoff criteria 
can be seen in Table 3, and were factors identified by the American Diabetes 
Risk 
value 
>25kg/m2 >200mg/
dL 
<40mg/
dL 
>100mg/
dL 
>150mg/dL >100mg/dL SBP>140mmH
g and DBP 
>90mmHg 
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Association and the American College of Cardiology Foundation in the concept of 
global cardiometabolic risk.7-10 This concept represents the overall risk of CVD.  
Clinical 
Blood pressure was measured by study staff after participants sat quietly for 
five minutes using an automatic blood pressure machine (Omron Healthcare Inc., 
Bannockburin Illinois). Blood pressure was taken twice or until readings were within 3 
mg/dL and the readings were averaged together.  
Additional Assessments 
All questionnaires were administered to participants by study personnel. A 
number of surveys and tests were administered to the participants at each time point. 
Additional questionnaires and tests that were administered but not analyzed in this 
study are as follows: the Swallowing Quality of Life Survey (SWAL-QOL), the 
Physical Activity and Disability Survey (PADS), a 14-item Resilience Questionnaire, 
and the Satisfaction with Life Scale (SWLS), the Short Physical Performance Battery 
(SPPB), and the Timed Up and Go (TUG) test. 
Statistical Analysis 
Data were analyzed using SPSS, version 23.0 for Windows(IBM Corp. 
Somers, NY). Descriptive statistics were performed and normality assessed using the 
Shapiro-Wilk test. Transformations or nonparametric tests were used to analyze non-
normally distributed data. Between group differences at T1 were determined via 
independent sample t-tests, Mann-Whitney U tests, and Fisher’s exact test. Hedge’s g 
was calculated to describe effect size for differences between groups (0.2 = small 
effect, 0.5 = medium effect, 0.8 = large effect).14 Repeated measures analysis of 
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covariance (RMANCOVA) was used to assess nutritional status over time looking at 
the dependent variable of nutritional status as measured by DST score. Partial eta2 was 
calculated to describe effect size for differences between groups over time (0.01 = 
small effect, 0.06 = medium effect, 0.14 = large effect).14 Analysis of covariance 
(ANCOVA) was used to assess the relationship at T1 of nutritional status on 
cardiometabolic risk factors and cognition using DST risk category as the independent 
variable. Cognition as RBANS score and the number of cardiometabolic risk factors 
served as the dependent variables. Covariates included were length of time since 
diagnosis and age, except for RBANS scores which are already age adjusted. Neither 
time since diagnosis nor age were found to be significant covariates in explaining any 
of the key dependent measures and were thus not used for analysis or in results 
presented here. For analyses in violation of Mauchly's test of sphericity, results were 
interpreted using the Greenhouse-Geisser correction. Analyses were considered 
significant when p < 0.05. 
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APPENDIX C: CONSENT FORM FOR RESEARCH 
 
Longitudinal Study of Communication, Nutrition and Physical Activity 
 
Leslie A. Mahler, PhD, Principal Investigator 
Ingrid Lofgren, PhD, co-Investigator 
Matthew Delmonico, PhD, co-Investigator 
 
CONSENT FORM FOR RESEARCH: Participant 
Version 2: July 30, 2013 
 
The University of Rhode Island 
Department of Communicative Disorders 
25 W Independence Square, Suite I 
Kingston, RI 02881 
 
Purpose of the Consent: 
You have been invited to take part in a research project described below. The purpose 
of the consent form you are about to read is to provide you with details about the 
research study and to inform you of your rights if you agree to participate in the study. 
Your participation is completely up to you. The researcher will explain the project to 
you in detail. You should feel free to ask questions. If you have more questions later 
you can call, Dr. Leslie Mahler, the person mainly responsible for this study, at 401- 
874-2490. You may also contact Dr. Ingrid Lofgren at 401-874-5706 or Dr. Matthew 
Delmonico at 401-874-5440, who are co-Investigators on the study. You must be at 
least 18 years old, speak English, and have neurological diagnosis of traumatic brain 
injury, stroke, or Parkinson disease to be in this research project. 
 
Description of the project: 
This is a research project designed to look at communication, nutrition, and physical 
activity characteristics of adults who have a stroke, traumatic brain injury or Parkinson 
disease. All evaluations will be conducted at one of two University of Rhode Island 
locations; in Independence Square on the Kingston Campus at 25 West Independence 
Way, Kingston or in Independence Square at 500 Prospect Street in Pawtucket. 
 
You are being asked to be in this study because we want to determine the long-term 
impact of neurological disorders on communication, nutrition, and physical activity. 
We are looking for 200 people who have a stroke, traumatic brain injury or Parkinson 
disease to participate in this project. Participation in this study is entirely your choice. 
 
If you decide to take part in this study, you should understand that the evaluations are 
investigational and you may not experience any benefit from participation. 
Participation may also involve additional risks as listed in the Potential Risks and 
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Discomforts section. The consent form will help make sure you understand the tasks 
included in the study before you decide whether you want to take part in the study. 
You may also quit the study at any time. 
 
What will be done: 
If you agree to take part in this study, you will be asked to complete up to 11 
evaluations over five years. Evaluations will take place every six months. The 
evaluations will include a variety of tasks such as reading sentences and describing a 
picture, an assessment of how your muscles move, a cognitive screening, an interview, 
a clinical swallowing evaluation, and questionnaires regarding swallowing, diet and 
physical activity. The total time for each evaluation will be approximately 3½ hours. 
All evaluations will be conducted in a quiet private room at one of the University of 
Rhode Island Speech and Hearing Clinic locations (Kingston or Pawtucket). 
 
With your permission, we will request health information from your physician about 
the following specific items only: 
Date of diagnosis 
Current medications 
Imaging information about where the brain damage is located (if appropriate) 
You will sign a separate form to indicate whether you give your permission to 
release this health information for the study. 
 
Potential risks and discomforts: 
There are minimal foreseeable risks associated with these evaluations. There have 
been no reported adverse affects from clinical evaluation of speech and swallowing. 
There may be some unknown or unanticipated risks, but every precaution will be 
taken to ensure your personal safety. Even though experienced personnel will obtain 
the blood samples from a finger prick, there is a chance of discomfort and minor 
bruising from the finger stick. For physical function testing there is a risk of muscle 
soreness or other muscle injury as well as skeletal injury but we will minimize these 
risks by using standard safety practices. 
 
Purpose and benefits of the study: 
The purpose of this study is to describe communication, nutrition, and physical 
activity behaviors over time to see how they change and affect quality of life. The 
information obtained is important because it will help us to understand how to provide 
services to meet the needs of people with neurological diagnoses. This is an 
investigational study and there is no guaranteed benefit to your communication or 
nutrition or physical function as a result of participation in this research study. You 
will receive personal health information such as your height and weight, physical 
function determined by a physical assessment, your blood lipids such as cholesterol 
and triglycerides. In addition, you will receive information about your thinking skills 
and language skills and dietary choices. 
 
Drugs, devices or instruments to be used: 
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Drugs will not be used in this study. The equipment for the evaluations include: 
microphone, sound level meter, tongue blade, a digital tuner, tape recorder, and video 
cameras. All equipment used to collect cognitive-linguistic and physical function data 
is considered non-invasive. A lancet and capillary tube will be used to obtain the blood 
sample from a finger prick and the sample will be analyzed on a small portable 
machine that is on a table. 
 
Cost to participant: 
There is no cost to you for participation in the evaluations. Parking is available for 
free. 
 
Confidentiality: 
Your part in this study is confidential. Your individual privacy will be maintained in 
all published and written data resulting from this study. No names of participants will 
be published or included in written data resulting from this study. Results of this study 
may be used for purposes of research, educational lectures, and/or professional 
presentations. When you are entered into the study you will be assigned a code that 
does not include any identifying information. For example, the first participant will be 
coded as Long01. The code number will be used on all response forms and in the 
analysis of the data. 
 
Dr. Mahler and her research team will have sole access to all contact information and 
evaluation results containing your name. This information will be kept in a locked 
filing cabinet in a locked office. However, the U.S. Department of Health and Human 
Services, and the University of Rhode Island Institutional Review Board have the right 
to inspect all of your records relating to this research for the purpose of verifying data. 
Because of the need to release information to these parties, absolute confidentiality 
cannot be guaranteed. Following completion of this project, contact information will 
be destroyed for those participants who wish, for any reason, not to be contacted in the 
future. All other information will be archived and kept in a locked filing cabinet with 
the study results at the University of Rhode Island. All research data will be retained 
for a minimum of three years following completion of the study and then will be 
destroyed. Research data will be located in a locked filing cabinet in the principal 
investigator’s locked office. 
 
Cognitive-linguistic evaluations will be audio and video recorded to allow for data 
analyses. At times these recordings can be useful for teaching students or professionals 
about the disorders of people with a neurological diagnosis such as yours. Please 
indicate by signing below whether you give your permission to use your samples for 
lectures and presentations. Audio and/or videotapes may be used for teaching for up to 
3 years after completion of the study. If you agree, you will never be identified by 
name in the presentations or lectures. Your decision to give permission to use audio 
and/or video samples in lectures has no impact on your participation in the study. 
 
 
_____________________ Yes, I give permission to use audio samples in lectures and 
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presentations. 
 
_____________________ Yes, I give permission to use video samples in lectures and 
presentations. 
 
______________________No, I do not want audio samples used except for research 
analysis. 
 
______________________No, I do not want video samples used except for research 
analysis. 
 
In case there is any injury to you during the study: 
If this study causes you any injury, you should immediately contact Dr. Leslie Mahler 
at (401) 874-2490 or contact the University of Rhode Island Speech and Hearing 
Clinic at (401) 874-5969. You may also call the office of the Vice President for 
Research Integrity, 70 Lower College Road, University of Rhode Island, Kingston, RI 
at (401) 874-4328. If you are injured during an evaluation or during treatment every 
effort will be made to get you medical attention but you will be responsible for paying 
for the medical treatment needed. 
 
Decision to quit at any time: 
The decision to take part in this study is up to you. You do not have to participate. If 
you decide to take part in the study, you may quit and stop participating in this study 
at any time. You have the right to refuse to answer any question(s) or participate in 
any procedure for any reason. Deciding not to participate will have no effect on your 
potential to receive services from a speech-language pathologist. If you wish to quit, 
simply inform Leslie Mahler at 874-2490 of your decision. If you wish to pursue an 
alternative treatment instead of completing the study you will be provided with 
information on how to obtain those services. 
 
Rights and complaints: 
If you are not satisfied with the way this study is performed, you may discuss your 
complaints with Dr. Leslie Mahler (lmahler@uri.edu; 401-874-2490), Dr. Ingrid 
Lofgren (ingridlofgren@uri.edu, 401-874-5706), or Dr. Matthew Delmonico 
(delmonico@uri.edu; 401-874-5440), or you may contact the office of the Vice 
President for Research for concerns or any questions about your rights as a research 
subject at: 70 Lower College Road, University of Rhode Island, Kingston, RI at (401) 
874-4328 and speak to them anonymously if you choose. 
 
 
 
 
 
 
 
 
  
90 
 
 
 
 
Authorization: 
Your authorization means that you have read this paper and know the purpose of the 
study and the possible risks and benefits. It also means you know that being in this 
study is voluntary and you choose to be in this study. You can also withdraw at any 
time. Your questions have been answered. Your signature on this form means that you 
understand the information and you agree to participate in this study. 
 
 
 
 
________________________   ________________________ 
Signature of Participant    Signature of Researcher 
 
 
 
 
_________________________   ________________________ 
Participant Typed/printed Name   Researcher Typed/printed name 
 
 
 
 
__________________________   _______________________ 
Date       Date 
 
 
 
________________________   ________________________ 
Signature of Guardian    Signature of Researcher 
 
 
 
_________________________   ________________________ 
Guardian Typed/printed Name   Researcher Typed/printed name 
 
 
 
__________________________   _______________________ 
Date       Date  
 
 
 
Please sign both consent forms, keeping one for yourself.
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APPENDIX D: ASSESSMENT MATERIALS 
 
INTERVIEW 
Longitudinal Study of Communication, Nutrition and Physical 
Activity 
Leslie Mahler, PhD, CCC-SLP, Principal Investigator 
Ingrid Lofgren, PhD, co-Investigator 
Matthew Delmonico, PhD, co-Investigator 
Version 2: 2-17-14 
 
Participant Name:_________________________ Initials: ___ ___ ___ ID#: ______________ 
Name of Interviewer:_____________________________ Date:_________________ 
 
Emergency contact name and address & phone: 
_______________________________________ 
_______________________________________ 
 
 
DIRECTIONS: Read the following questions out loud to each prospective volunteer 
and record the answers. Any answers that require clarification should be written in the 
space below the question or on the back of the sheet. Indicate whether any follow-up 
is necessary or if any referrals are appropriate. 
 
What is your neurological diagnosis? __________________________ 
When were you diagnosed? _________________________________ 
What were your symptoms at that time? 
_____________________________________________________________________ 
What are your symptoms now? 
_____________________________________________________________________ 
What is your communication like? 
_____________________________________________________________________ 
What is your diet like? 
___________________________________________________________ 
What is your physical activity like? 
________________________________________________ 
117 
Does your speech sound clear to other people? 
_________________________________________ 
If not, how does it sound? 
___________________________________________________ 
Can you think of the words that you want to say? 
______________________________________ 
If you do have trouble, how often does it happen? 
__________________________________ 
Are you experiencing any symptoms of a swallowing disorder? ____________ 
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If yes, what is the problem with your swallowing? 
__________________________________ 
What would you say is your most significant problem with speech or swallowing 
today?________________________________________________________________ 
_________________________________________ 
Did you experience any changes in your speech or swallowing before your diagnosis? 
_____________________________________________________________________ 
Does medication affect your speech or voice or swallowing? _________ 
If yes, in what way? _____________________________________________ 
 
Speech 
How many hours of speaking do you do in a day? _________________________ 
What is a typical day of communicating like for you? 
_____________________________________________________________________ 
_____________________________________________________________________ 
Do you pronounce your words clearly? 
____________________________________________ 
Do people ask you to repeat yourself? 
______________________________________________ 
Do people have a hard time understanding you? 
______________________________________ 
118 
What do you do when you want to be as easy to understand as possible? 
_____________________________________________________________________ 
_____________________________________________________________________ 
What percent of your speech do you think is understandable? 
_____________________________________________________________________ 
Has your neurological diagnosis caused you to talk less? 
_____________________________________________________________________ 
If so, how much less? ___________ Why?__________________________________ 
_____________________________________________________________________ 
 
Swallowing 
Do you have any difficulty with swallowing? 
___________________________________ 
Do you cough during mealtimes? _____________________ 
If yes, do you cough more with water or solid food? _________________ 
Do you have difficulty making the food go down (need to swallow twice)? 
________________________________________________________________ 
Does it take you longer to finish a meal than before your neurological diagnosis? 
__________________________________________________________ 
Have you experienced any unintentional recent weight loss? _____________ 
Have you ever been diagnosed with pneumonia? ____________ 
If yes, when? _____________ 
Have you changed your diet since your neurological 
diagnosis?___________________ 
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If yes, what did you modify? ___________________________________ 
119 
Musculoskeletal system: 
Has your doctor ever told you that you have: (circle all that apply) 
Osteoarthritis or degenerative arthritis 
Rheumatoid arthritis 
Osteoporosis 
Ankylosing Spondylitis 
Unknown or other type of arthritis 
Any other disease of joint or muscle: 
Comments: 
Cardiovascular system: 
Has any family member had a heart attack prior to the age of 55? 
o If so, how are they related to you? 
Have you ever had frequent cramping in your legs while resting? 
o If yes, is it a current problem? _____________________________ 
Have you ever had pain or cramping in your legs while walking? 
o If yes, is it a current problem? ________________________________ 
If yes, is this pain relieved by rest or by discontinuing walking?___________ 
Have you ever been told that you have high blood pressure 
o If yes, what was the date of onset? ____________________ 
o Were you given any medications? ______________ 
Did a doctor ever tell you that you had a heart problem? 
o If yes: What was the date of onset? _______________________ 
What did the doctor call it? _________________________________ 
o Were you given any medications? ____________________________ 
Do you have any history of high cholesterol in your blood as evidenced by a 
previous blood lipid tests? 
________________________________________________________ 
Comments:___________________________________________________ 
120 
Endocrine system: 
Have you ever had any of the following: Thyroid problems, adrenal problems, 
diabetes mellitus? 
____________________________________________________________ 
If yes to diabetes, which type? Type 1 or Type 2 
Date of onset- _________________________ 
Are/were you on any medication, or is it diet controlled? 
____________________________________________________________ 
Neurological system: 
Do you have any significant problems with your memory? (circle all that apply) 
o When answering the telephone, do you recall what you were doing before it rang? 
o Can you give the directions to your house/apartment? 
o Can you keep appointments without a reminder? 
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o Can you remember what clothes you wore yesterday? 
Any problems with vision other than corrective lens changes? 
o If yes, which of the following conditions- Blindness, temporary loss 
of vision, double vision, glaucoma, cataract, macular degeneration or others. 
_________________________________________________________ 
Do you have and of the following?: (circle all that apply) 
Vertigo (a feeling of spinning, or unsteadiness) 
Seizure or convulsions? 
Migraine or severe headaches? 
Paralysis of arm or leg? 
A head injury with loss of consciousness? 
Pain, numbness or tingling in your limbs? 
Pain in your lower back? 
121 
Do you have pain in any part of body including headaches while exercising? 
Have you been told that you have a peripheral neuropathy? 
Tremors? 
Problems with walking? If yes, 
o Do you fall frequently? 
o Is your walking problem related to pain, weakness or loss of balance? 
Have you ever had an operation on skull or brain? 
Have you ever had meningitis or Brain fever? 
Comments: 
Previous Treatment 
Have you had previous speech or swallow treatment, occupational therapy or physical 
therapy? _____________________________________________________________ 
If yes, please describe (when, what) 
_____________________________________________________________________ 
_____________________________________________________________________ 
Was it beneficial? 
_____________________________________________________________________ 
If yes, what changes did you notice? 
_____________________________________________________________________ 
_____________________________________________________________________ 
Employment 
Are you employed? 
___________________________________________________________ 
Type of employment 
__________________________________________________________ 
122 
How much speaking do you do at your job? 
_____________________________________________________________________ 
_____________________________________________________________________ 
Smoking Status 
Do you currently smoke cigarettes? ___________________________ 
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Do you have a history of smoking cigarettes? ___________________ 
If you have quit smoking cigarettes, how many months/years ago did you quit? 
___________________ 
Other 
Have you noticed any difficulty with your memory? 
_____________________________ 
Have you experienced any changes in your mood? 
_______________________________ 
Is it difficult for you to pay attention long enough to finish a task? 
___________________ 
Do you have any difficulty reading? ____________________________________ 
Do you have any difficulty writing? ___________________________________ 
Do you have any other health problems or conditions that would affect 
communication, nutrition or physical activity? 
____________________________________________________________________ 
Are you Hispanic or Latino? _______ 
What race do you identify with? (Check all that apply) ______ I prefer not to provide 
this information 
White/Caucasian ______ African American_______ Asian _______American 
Indian/Alaskan Native______ Native Hawaiian/Pacific Islander_______ 
Other_______ 
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Dietary Screening Tool 
 
DIRECTIONS: Please check one response to each question that best 
describes how you eat. 
 
How often do you usually eat fruit as a snack? 
____ Never 
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you usually eat whole grain breads? 
____ Never or less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you usually eat whole grain cereals? 
____ Never or less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you usually eat candy or chocolate? 
____ Never 
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat crackers, pretzels, chips, or popcorn? 
____ Never 
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat cakes or pies? 
____ Never 
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat cookies? 
____ Never 
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
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How often do you eat ice cream? 
____ Never 
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
How often do you eat cold cuts, hot dogs, lunchmeats or deli meats? 
 
____ Never or less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat bacon or sausage? 
____ Never or less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat carrots, sweet potatoes, broccoli, or spinach? 
____ Never 
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat fruit (not including juice)? Please 
include fresh, canned or frozen fruit. 
____ Never or Less than once a week 
____ 1 or 2 times a week 
____ 3 to 5 times a week 
____ Every day or almost every day 
 
How often do you eat hot or cold breakfast cereal? 
____ Never 
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 to 5 times a week 
____ Every day or almost every day 
 
How often do you drink some kind of juice at breakfast? 
____ Never or Less than once a week 
____ 1 or 2 times a week 
____ 3 to 5 times a week 
____ Every day or almost every day 
 
How often do you eat chicken or turkey? 
____ Never or less than once a week 
____ 1 or 2 times a week 
____ More than 3 times a week 
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How often do you drink a glass of milk? 
____ Never or Less than once a week 
____ 1 or 2 times a week 
____ 3 to 5 times a week 
____ Every day or almost every day 
____ More than once every day 
 
Do you usually add butter or margarine to foods like bread, 
rolls, or biscuits? 
____ Yes 
____ No 
 
Do you usually add fat (butter, margarine or oil) to potatoes 
and other vegetables? 
____ Yes 
____ No 
 
Do you use gravy (when available) at meals? 
____ Yes 
____ No 
 
Do you usually add sugar or honey to sweeten your coffee or 
tea? 
____ Yes 
____ No 
 
Do you usually drink wine, beer or other alcoholic 
beverages? 
____ Yes 
____ No 
 
How often do you eat fish or seafood that IS NOT fried? 
____ Never 
____ Less than once a week 
____ Once a week 
____ More than once a week 
 
How many servings of milk, cheese, or yogurt do you usually 
have each DAY? 
____ None 
____ One 
____ Two or more 
 
How many different vegetable servings do you usually have 
at your main meal of the day? 
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____ None 
____ One 
____ Two 
____ Three or more 
 
Which of the following best describes your nutritional 
supplement use. 
____ I don’t use supplements 
____ I use supplements other than vitamins and mineral 
 
